EMERGING MEDICAL TECHNOLOGIES® SPOTLIGHT

• Online Database
• PDF
• eBook

• Search by Keyword/Market (e.g., heart valve, orthopedics, etc.)
• Search by Company Name

The Online Database Format Includes Advanced Searching:

Keyword & Exact Phrase Searching:		Search By Medical Market:
Search By Conference:		Search By Company Name:
Search By Region:

Technology descriptions for companies currently covered as of 05/18/12 include:

• Company 1 - Spiral Laminar Flow (SLF) prosthetic grafts are used to reproduce the body's natural blood flow patterns and treat cardiovascular disease
• Company 2 - Novel MRI scanner to diagnose disease and provide real time guidance of thermal energy procedures such as lesion biopsies and tumor treatments
• Company 3 - Minimally invasive ultrasound device that allows for rapid evaluation of fallopian tubes to assess fertility at point of care
• Company 4 - Cellular Regeneration Technology (CRT) utilizing cell interaction and a functional polymer scaffolding to provide a single-surgery treatment for damaged articular cartilage in the knee
• Company 5 - Second-generation biomimetic cardiovascular prostheses that are coated with transformational proteins to prevent post operative rejection
• Company 6 - Non-invasive system to detect and alert users of sleep-time hypoglycemia for the monitoring of type 1 diabetes
• Company 7 - Innovative products designed to alleviate pain and enhance physical comfort in those affected by illness, disability, injury, pressure and poor ergonomics
• Company 8 - Oral active molecule therapeutic to improve memory and learning in patients with Alzheimer's Disease
• Company 9 - Novel cervical collar used in emergency situations to immobilize the neck while chemically cooling to lower brain temperature to slow metabolism, improve cell membrane stability and reduce inflammation
• Company 10 - Diagnostic test for lung cancer using biological olfactory sensor arrays
• Company 11 - Innovative medical isotopes and cancer treatment elements used in thyroid and respiratory cancer therapies
• Company 12 - Novel small molecules and monoclonal antibodies for the treatment of vascular disease and to enhance wound healing, specifically diabetic macular edema and inflammatory bowel disease
• Company 13 - In vivo positron emission tomography imaging agents to detect cancer and autoimmune disease
• Company 14 - Novel therapeutics to remove acetaldehyde and other toxic aldehydes that impair protein function and cause mutation in DNA
• Company 15 - First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer's
• Company 16 - Novel anti-angiogenic cancer therapy that inhibits blood supply to prevent tumor growth
• Company 17 - G protein-coupled receptor therapeutics to combat multiple sclerosis
• Company 18 - Novel therapy to treat iron overload caused by chronic transfusion therapy
• Company 19 - Blood-based molecular diagnostics that track multiple biomarkers for early diagnosis of a variety of diseases including cancer and Alzheimer's
• Company 20 - Magnetically targeted drug delivery system enabling patient specific delivery options to treat peripheral artery disease
• Company 21 - First-in-class oral therapeutic to disrupt the natural course of lactose intolerance by stimulating lactose-metabolizing bacteria in the colon and offering long-term symptom relief
• Company 22 - Molecular test to detect pathogens and bacteria that can lead to nosocomial infections
• Company 23 - Novel non-invasive test to asses infertility and egg quality in women through the use of genetic biomarkers
• Company 24 - Aneurysm embolization system that promote rapid, peri-procedural stasis in wide neck ruptured and unruptured aneurysms, taking the place of traditional coils
• Company 25 - Novel monoclonal antibody therapies targeting receptor tyrosine kinases to treat cancers
• Company 26 - Small molecule therapeutics to treat cardiometabolic diseases including dyslipidemia/hypercholesterolemia and diabetes
• Company 27 - Novel front-line therapies for the treatment of inflammatory bowel disease, specifically ulcerative colitis
• Company 28 - Novel therapeutics to treat diseases affecting mucosal tissue
• Company 29 - Oral therapeutics that inhibit the breakdown of calcitonin for the treatment and prevention of osteoporosis and related bone disease
• Company 30 - Comprehensive portable device to provide point-of-care diagnostics for a variety of diseases
• Company 31 - Point-of-care molecular diagnostic device utilizing electrochemicals to provide rapid, enzyme-free detection of nucleic acids for infectious disease
• Company 32 - Peptide-based immunotherapy intended to treat and prevent pancreatic cancer by targeting mutated ras genes
• Company 33 - Orthobiologic implant to fill bone voids utilizing parathyroid hormone peptides to prevent further bone loss in osteoporosis and spinal injuries
• Company 34 - Invasive fractional flow reserve device analyzer that uses computed tomography images to determine arterial blood flow and pressure, allowing better diagnosis of ischemic stenosis
• Company 35 - Selective small molecule histone deacetylase inhibitors to treat multiple myeloma with possible indications for inflammatory, neurodegenerative, infectious and genetic disease
• Company 36 - Small molecule therapeutics for acute central nervous system disorders; the company's lead product is intended to reduce brain swelling and hemorrhage resulting from ischemic and traumatic injury
• Company 37 - Innovative aortic valvuloplasty balloon for the treatment of calcific aortic stenosis
• Company 38 - Novel allogeneic cell graft with copper chelator technology for use in bone marrow transplants to treat leukemia and lymphoma in patients without an available familial donor
• Company 39 - Sophisticated implants and surgical tools featuring a biomechanically-compliant nail for the fixation of hip fracture in third age patients suffering from osteoporosis
• Company 40 - Novel screening technology based on oncoproteins to differentiate benign infection from true disease and detect cervical cancer and other cancers associated with human papillomavirus (HPV)
• Company 41 - Novel therapeutics that inhibits translation of neurotoxic proteins for the treatment of neurodegenerative disorders, including Alzheimer's and Parkinson's
• Company 42 - Innovative refractive ophthalmologic surgery technologies and instruments for flapless epithelial surface removal and the treatment of keratoconus
• Company 43 - Colorimetric blast dosimeter provides immediate information as to the level of blast exposure relative to brain injury via a color change imaging technology
• Company 44 - Innovative dental implants, prosthetics, bone graft materials and surgical tools to treat oral ailments with minimally invasive technologies
• Company 45 - Non-invasive medical devices and mobile health applications utilizing acoustic respiratory monitoring technology to improve the management of chronic respiratory diseases including asthma and COPD
• Company 46 - Small molecule oral therapeutic that combats osteoporosis and builds bone by inhibiting the activity of the Sclerostin protein
• Company 47 - Breakthrough implantable stimulation system that uses neuromodulation to treat refractory epilepsy
• Company 48 - Ultrasound instrument that combines light and doppler technology to monitor the efficacy of advanced breast cancer therapies; also offers a light-only version for home health
• Company 49 - Oncology and companion diagnostics with special capabilities in the area of mRNA and miRNA
• Company 50 - Biodegradable drug delivery implants to treat and prevent wound infection and manage pain
• Company 51 - Novel implantable and external brain stimulation devices for the treatment of neurological disorders
• Company 52 - Warm blood perfusion system to preserve hearts and lungs for transplantation
• Company 53 - Innovative drug candidates to reduce intraocular pressure and treat retinal diseases
• Company 54 - Osteoporosis treatment through novel nasal spray
• Company 55 - Technologies for genetic analysis preparation to predict disease risk and drug response
• Company 56 - Novel first-in-class pharmaceuticals to improve vascular access in renal and vascular diseases
• Company 57 - Small molecule therapies for neurodegenerative diseases
• Company 58 - Topical mechlorethamine gel therapy for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma
• Company 59 - Novel oral therapeutics to treat cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and neurodegenerative disorders
• Company 60 - Antithrombotic therapies for use in acute and subacute care
• Company 61 - Inhaled therapies to treat and prevent respiratory conditions including infections, progressive diseases, and allergic rhinitis
• Company 62 - Therapeutics to treat disease-associated pain and inflammation
• Company 63 - Novel electronic whole-genome sequencing employing solid-state technology
• Company 64 - Novel prescription products targeting reduced submental fat
• Company 65 - Antibiotics focused on Riboswitches (RNA drug targets) to treat drug resistant fungal and bacterial pathogens
• Company 66 - Novel therapeutics for the treatment of drug addiction and smoking cessation through reduction of craving function in brain
• Company 67 - Gene-, protein-, and serum-based biomarker analysis technology to identify potential cancer
• Company 68 - Novel therapeutic antibodies for the treatment of infectious disease, cancer and inflammation
• Company 69 - Automated microfluidic systems and instrumentation for single-cell analysis
• Company 70 - Natural color dental implants to restore function and aesthetics
• Company 71 - Antiviral pharmaceuticals that bind to caspids to treat HIV and HBV
• Company 72 - Live tumor cell processing platform for predictive testing which uses functioning signaling profiles to guide cancer therapy
• Company 73 - Novel molecular therapies for the treatment and prevention of metabolic disease associated with altered mitochondrial function
• Company 74 - High concentrate Omega-3 fatty acids for use in pharmaceuticals, developed from algae
• Company 75 - Novel molecules to target chronic T-cell mediated inflammatory diseases
• Company 76 - Point-of-care blood and urine analyzer to detect infectious disease and test blood levels; lab-quality results available within minutes of testing
• Company 77 - Atraumatic, self-retaining surgical tissue retractors for thyroidectomy and related procedures that feature low profile, disposable designs
• Company 78 - Vertical lumbar traction system to realign spine, reduce disc herniation and lower back pain
• Company 79 - Double-balloon urinary drainage catheter designed to prevent catheter cystitis, urinary tract infections and septicemia
• Company 80 - Biopolymer implants, biomaterials and therapeutics to repair damaged heart structure and treat congestive heart failure
• Company 81 - DNA-based diagnostic tests used to detect diseases and conditions affecting women, such as endometriosis, infertility, and pre-term labor
• Company 82 - Brain Anaesthesia Response (BAR) monitoring system to improve existing EEG technology and reduce intra-operative awareness
• Company 83 - High-quality reconstructive total joint implants for the hip and knee
• Company 84 - Whole-Body Thermometry (WBT) advanced medical diagnostic device for non-invasive analysis, including tissue signature disorder recognition
• Company 85 - Innovative technologies for patient monitoring to include neurological, cardiovascular and pain management indications
• Company 86 - Novel allogeneic cell-derived biomaterials that do not require synthetic scaffolds and are used to regenerate cardiovascular and other soft tissues
• Company 87 - Innovative instrument to simplify insertion of artificial spinal disc implants
• Company 88 - ICDR, a simple yet sophisticated Internal Cavity Drug Retention system for controlled and highly effective delivery of therapeutic agents into the bladder. Based on advanced materials technologies, the ICDR system improves drug bioavailability and reduces toxicity, significantly enhancing treatment potential, safety, and compliance.
• Company 89 - An innovative enabling platform technology that harvests tens of millions of a patient's own adipose-derived regenerative cells in one hour, for immediate application
• Company 90 - Disposable medical device to improve stroke risk during heart bypass procedures
• Company 91 - A pioneering ozone-oxygen-vacuum system for healing chronic, hard-to-heal wounds. The technology is non-invasive and medically proven for diabetic foot, PVD, venous ulcers, and more.
• Company 92 - EpiLert is a wireless, watch-like device providing real-time ALERT to CAREGIVERS of an ongoing epileptic seizure
• Company 93 - Resin-based vehicles that quickly deliver medications transmucosally to the bloodstream and formulations that treat such conditions as smoking cessation, anxiety, chronic breakthrough pain, and migraines
• Company 94 - The Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI/MBI - a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake
• Company 95 - Self-adjustable vaginal ring pessary to treat urinary incontinence and genital prolapse without drugs
• Company 96 - Novel thyroid FNA analysis technology combines cytopathology and Afirma Gene Expression Classifier for nodule assessment
• Company 97 - Next generation G-protein coupled receptor-biased ligand pharmaceuticals which are intended to limit adverse drug effects
• Company 98 - Novel biotherapeutic technologies featuring self-contained subcutaneous delivery mechanisms
• Company 99 - Innovative ultra-sensitive immunodiagnostic systems for use in research and in-vitro diagnostics
• Company 100 - Therapeutics based on natural killer cells (NKT), a subset of immune cells, intended for the treatment of autoimmune and inflammatory diseases in addition to asthma, cancer, and dermatitis
• Company 101 - Innovative antibiofilm catheter lock technology to reduce infection associated with indwelling catheters
• Company 102 - Patient-specific epigenetic therapeutics utilizing small molecule histone methyltransferase (HMT) inhibitors for the treatment of cancer
• Company 103 - Expanding hydraulic implant for use in lumbar spinal fusion procedures
• Company 104 - Novel small molecule therapies for respiratory disorders
• Company 105 - Novel diagnostics utilizing protein based biomarker technology focused on nosocomial disease
• Company 106 - Targeted oral therapeutics to correct mineral metabolism and metabolic disorders
• Company 107 - Proprietary implant technology featuring a hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea
• Company 108 - Cosmetic and drug delivery systems based on nanotechnology
• Company 109 - Innovative therapies utilizing pepducins to modulate G-protein receptors, thereby expanding treatments for cancer, diabetes, inflammation, and regenerative medicine
• Company 110 - Therapeutics for the treatment of post-operative and chronic pain
• Company 111 - Novel ophthalmic therapies to treat ocular diseases
• Company 112 - Third-generation transcatheter aortic valve prosthesis with increased safety, greater ease-of-use, and longer durability
• Company 113 - Ultrasonic devices for non-invasive fat removal from the chin, arm, and eye-bags and for skin tightening
• Company 114 - The Rx Timer Cap is a patented "smart cap" with a built-in LCD timer that fits common prescription vials and lets patients know exactly how long it has been since they last took their medication
• Company 115 - Sutureless, adjustable mitral annuloplasty toolset for surgical and robotic procedures
• Company 116 - A novel annuloplasty ring for heart valve repair. The Intra-annular Ring represents a unique solution for children allowing the valve to grow following implantation.
• Company 117 - The first home-based telemonitoring system for patients with age-related macular degeneration, the leading cause of blindness in people over age 50 in the western world
• Company 118 - A nanotechnology-enabled portfolio of therapeutic products for use in medical applications
• Company 119 - Proprietary technology for decellularizing biological organs/tissues to create an extra-cellular matrix retaining its original architecture, mechanical properties, and vascular network - suitable for scaffold transplantation or growing new functional organs/tissues by recellularization
• Company 120 - A battery-powered device which lifts and acquires a healthcare patient weighing up to 500 lbs. - without any caregiver's touching, logrolling, or lifting - and transports them to the next destination, then gently discharges them onto the desired horizontal surface
• Company 121 - The patented EXMI technology uses pulsed magnetic fields that penetrate up to 7,5 cm into the body, stimulating nerves (neuromodulation), contracting muscles (rehabilitation), treating pain/depression, and increasing blood flow
• Company 122 - Requiring only one drop of blood, the proprietary LBIdx(TM) Plasma Thermogram(TM) tests will significantly improve the clinical diagnosis and monitoring of autoimmune disease and cancer, vastly improving patient outcomes
• Company 123 - New gene-based medicines to treat "dominant" genetic diseases, particularly for the eye
• Company 124 - Technology that provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes. The method is convenient, easy-to-use, and validated. It measures tissue accumulation of Advanced Glycation End products (AGEs) by means of fluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes and cardiovascular disease.
• Company 125 - An oral delivery platform for medications, food supplements, and other soluble substances that is easy-to-use, friendly, inexpensive, and requires no third-party assistance
• Company 126 - Ventritek 105 is a novel medical device that provides full treatment for Stroke/SAH/ICH patients by replacing the current long and risky procedure
• Company 127 - An inhaler with variable dosage of Asthma medicine, based on a built-in exhaling measurement of the airway obstruction level
• Company 128 - The RGS Vertex360(TM), which competes with the Gamma knife in the non-invasive treatment of brain tumors, is a highly precise cobalt 60 radiation system that utilizes the OsiriX(TM) based Explorer 4D(TM) treatment planning system, also developed by the company
• Company 129 - Innovative central nervous system therapies; Allon is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP)
• Company 130 - Vaccine platform technology for cancer and infectious diseases based on Listeria monocytogenes that has been engineered to be safe for use in humans and express specific disease antigens
• Company 131 - Real-time, non-contact, high resolution tissue temperature monitoring & mapping products that improve the safety and efficacy of ablation therapy by avoiding injury to surrounding tissue
• Company 132 - Oncology drugs that utilize novel mechanisms of action
• Company 133 - Electronic stimulation technologies that maintain muscle strength during recovery in the intensive care unit or other periods of inactivity
• Company 134 - The fentanyl iontophoretic transdermal system (IONSYS), an investigational, pre-programmed drug delivery system comprising a compact, needle-free, self-contained system that provides patient-controlled analgesia for adult inpatients requiring post-operative opioid therapy
• Company 135 - Two novel technologies that boost immune responses, including a synthetic toll-like receptor agonist for use as an adjuvant to vaccines , and a viral vector that targets immature dendritic cells
• Company 136 - A molecular diagnostics test that examines somatic alterations in cancer-related genes by applying massively parallel sequencing to routine clinical specimens, enabling targeted therapy
• Company 137 - Nanofibers designed for use in tissue engineering, drug delivery, and wound care
• Company 138 - Vascular closure device that seals the femoral artery following cardiac catherization
• Company 139 - An aerosolized long-acting muscarinic antagonist that treats chronic obstructive pulmonary disease (COPD)
• Company 140 - Novel metal abstraction peptide (MAP) platform technology that delivers platinum to cancer cells by incorporating it into cancer-targeting proteins, thereby improving treatment while limiting side effects and damage to healthy cells
• Company 141 - Long-acting, intravenous lipoglycopeptide used to treat acute bacterial skin and skin structure infections
• Company 142 - Innovative new topical therapies for dermatology applications, including photodynamic therapy for sebaceous gland disorders and small molecule therapeutics that treat acne, inflammatory skin diseases, and sebaceous gland hyperactivity
• Company 143 - Novel, minimally invasive surgical devices for the treatment of sinusitis
• Company 144 - Novel drugs that treat cancer by targeting cellular protein homeostasis pathways
• Company 145 - A next-generation eye drop medication that uses Rho-kinase inhibitors to treat glaucoma
• Company 146 - Minimally invasive spinal disc regeneration technologies (SRTs) with a goal of biologically regenerating the tissues of the disc to restore the natural visco-elastic, biomechanical, and fluid characteristics of the inner core and outer tensil ring
• Company 147 - MedApps' solutions utilize cloud computing to connect patients and professional care providers, enabling proactive healthcare delivery
• Company 148 - Novel 3D cell culture devices for stem cell, tissue engineering, cancer, and drug discovery applications
• Company 149 - Developing a whole-plant therapeutic, AMZ0026, that exhibits immunomodulator properties for the treatment of HIV/AIDS. Preliminary clinical studies in patients that are seropositive for HIV-1 have demonstrated a positive effect on CD4 and CD4/CD8 blood serum levels.
• Company 150 - A Leptin product as a novel hormone replacement therapy for Alzheimer's disease (AD) and/or as a preventative for those who are at risk
• Company 151 - EMMA (Electronic Medication Management Assistant) - a remote medication administration unit that is placed in a patient's residence to enable a healthcare professional (i.e., pharmacist or nurse) to remotely administer their oral medications
• Company 152 - A disruptive next-generation low profile (14 French), pre-mounted and pre-packaged "package-to-patient" percutaneous Transcatheter Heart Valve (THV)
• Company 153 - EPIFLO utilizes cutting-edge oxygen concentration technology to create tissue regenerative processes driving closure of delayed-healing acute or chronic wounds
• Company 154 - Drugs to treat dry Age Related Macular Degeneration (dAMD) and other vascular diseases of the eye, including Glaucoma, DME, and Diabetic Retinopathy
• Company 155 - Endoluminal device for incisionless treatment of obesity
• Company 156 - Software that can read and analyze the image stack of a CT scan and draft a report that includes major pathological findings, identification of key images, and quantitative measurements - provided to the radiologist at the customers site
• Company 157 - Developer of easy-to-use genetic tests (clinically validated DNA SNP patterns) that empower individuals to prevent certain chronic conditions and manage their existing health and wellness through actionable guidance
• Company 158 - A therapeutic for HIV that is divergent from current approaches, in that rather than fight against HIV's greatest strengths - mutation frequency & rate of replication - the drug exploits these "strengths" to cause viral population collapse
• Company 159 - A device that uses non-invasive ultrasound to disrupt the blood-brain barrier, for delivery of large molecule therapeutics to treat primary and metastatic brain tumors
• Company 160 - The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology, and molecular genetic testing
• Company 161 - Developing healthier drugs from whole-plants. MAHDL, developed to elevate HDL-C, has undergone tests in man with positive results and has an IND from the FDA. Other whole-plant therapeutics are under development for dementia.
• Company 162 - ZeroFold, the lowest profile balloon available for improving deliverability and effectiveness of balloon angioplasty catheters
• Company 163 - A revolutionary technology to sterilize proteins in dehydrated formulations by irradiation (beta, gamma) or Ethylene Oxide
• Company 164 - Next-generation vaccines based on patented LAMP Technology that induce a strong and complete immune response, with applications in allergy, cancer, and infectious disease
• Company 165 - The world's first homozygous parthenogenetic stem cell lines that can provide therapeutic cells with the potential to be transplanted into hundreds of millions of individuals of differing ages and racial backgrounds with minimal risk of immune rejection
• Company 166 - A web-enabled, low level electromagnetic therapy system, that provides HealthCare providers in the Complementary and Alternative Medicine (CAM) marketplace with a device that improves both their Patients' Health and their Business
• Company 167 - Bioluminescent (light producing) proteins and related substrates that can: 1-be used as an adjunct to surgery, including laparoscopy, 2-track the progression of disease and evaluate the effectiveness of therapy, and 3-diagnosis a disease process before there are symptoms or anatomical features such as tumors
• Company 168 - A patented ultrasound miniaturization technology which has enabled the creation of iPod sized ultrasound pain therapy systems with unprecedented operation times of up to 6 hours on a single cell phone battery
• Company 169 - Miniaturized, hand-held, instrument-mounted optical measurement and navigation systems for surgical applications
• Company 170 - Turnkey SaaS software solution that dramatically reduces errors, turnaround times, and costs of MRI, CT, and PET-CT diagnostic reports
• Company 171 - Fast-track development of novel drugs for an unmet medical need - Alzheimer's disease - with rapid payback on investment
• Company 172 - Technology platforms that improve surgical efficiency in complex orthopedic procedures such as total joint replacement, spinal fusion, and trauma fixation: 1-For medical device manufacturers, RepAssist(TM) reduces training costs, dramatically compresses the time it takes for new reps to provide value in the OR, and enhances rep efficiency with existing accounts. 2-For hospitals/surgery centers, Virtual Backtable(TM) significantly enhances OR team proficiency in organizing and utilizing instrumentation, independent of the team's experience level with the implant system or surgeon, resulting in improved surgical efficiency and higher surgeon satisfaction.
• Company 173 - Implantable devices that allow surgeons to reduce the morbidity of spinal deformity surgery with a procedure that is quicker, safer, and more cost-effective than existing techniques
• Company 174 - Minimally invasive, joint preserving treatment option for chronic knee osteoarthritis (OA) pain; an alternative to total knee replacement (TKR)
• Company 175 - A broad platform of minimally invasive intramedullary devices to improve fracture fixation, reduce soft tissue trauma, and speed the patient's return to normal daily activities
• Company 176 - Intra-articular ion channel modulators for the treatment of osteoarthritis (OA) in all synovial joints
• Company 177 - A breakthrough platform technology that provides highly porous (>65%), load-bearing orthopedic implants in both surface active (metal, ceramic) and resorbable materials
• Company 178 - An easy-to-use, low-cost, point-of-care (POC) ELISA-based adjunctive screening kit, specifically for oral cancer
• Company 179 - A neurostimulation technology to improve function and independence after stroke
• Company 180 - Novel portable diagnostic tool to detect a wide variety of protein analytes and un-amplified DNA at point of care
• Company 181 - Hand-held smart drill with robotic technology that provides: safe depth control, accurate depth measurement, bone density measurement, and performance feedback for orthopedic and spine applications
• Company 182 - An affordable drug delivery pump/patch that is cost-competitive with pre-filled pen injectors and offers a superior end-user experience
• Company 183 - A disruptive, non-invasive, and long-term neuro-monitoring technology with the potential to reduce stroke and damage from aneurysms, tumors, and other neurologic trauma
• Company 184 - A minimally invasive stent platform that offers safe, simple, and accelerated healing for the treatment of endoluminal diseases
• Company 185 - MGI Medical's "Pulse Flowmeter" provides sensitive, early detection of hemodynamic instability through continuous, non-invasive assessment of peripheral blood flow. This permits early detection and management of blood loss and/or heart failure when there have been no changes in vital signs.
• Company 186 - An ultrasensitive hand-held probe that is capable of detecting specialized, subcutaneously injected magnetic materials and is used to locate lymph nodes to support the diagnosis and treatment of cancer
• Company 187 - A non-invasive, accurate, and easy-to-use female fertility monitor
• Company 188 - A low-cost incision guide that is applied with an adhesive sticker before a medical scan and leaves behind an ink imprint of locational markings (such as a grid or ruler) on the patient's skin so that the surgeon can accurately correlate target locations with the medical image
• Company 189 - Technology that enables and facilitates seamless stenting of all coronary bifurcation disease scenarios
• Company 190 - A biopharmaceutical company with an extensive library of structurally diverse bioactive peptides with broad applications in the health, beauty, and pharmaceutical industries
• Company 191 - 1-A spray drying technology to enable the storage of plasma in diverse environments by methods that are far simpler/less costly than those used currently and 2-A product to enable platelets to be stored in refrigerators rather than at room temperature to: (i) improve safety, (ii) extend shelf life, and (iii) significantly reduce costs
• Company 192 - A mechanical thrombectomy kit that will help restore blood flow and reduce hemorrhagic complications associated with acute ischemic stroke therapy
• Company 193 - Miniature infrared thermal imaging cameras combined with a spectroscopic infrared real-time in vivo analysis device for the early detection/accurate identification of internal lesions and tumors, as an add-on to existing endoscopes
• Company 194 - A unique lipid-soluble anti-oxidant heavy metal chelator that is safe and effective, for which the company is pursuing orphan drug approval
• Company 195 - ImplantLock, a device that enables a safe alternative to vertical bone augmentation or sinus lifting as well as immediate functional loading even after tooth extraction
• Company 196 - Advanced medical technology that combines CO2 laser capabilities with autologous stem cells to significantly improve cardiac output in patients with heart disease or heart failure
• Company 197 - A take-home conception aid system that is designed to address the growing unmet need of delayed/unsuccessful natural fertility that historically has had similar results to intrauterine insemination (IUI), yet can now be done in the privacy of the home
• Company 198 - Integrated molecular diagnostic system that is easy to use and requires little or no training
• Company 199 - Technologies that: 1-Temporarily plug body passageways with a thermo-transitioning gel that is delivered as a cold liquid, solidifies at body temperature, and is later flushed away and 2-Keep body passageways open with gentle passively dilating devices, as well with more rigid construction of an open design, to prevent eventual long-term blockage
• Company 200 - Non-invasive disposable device to automatically deliver a new therapy called *Remote Ischemic Preconditioning*, an adjunct to traditional treatments for heart attack and stroke that mitigates ischemia-reperfusion injury and has been clinically shown to reduce infarct size by 50%, without side effects
• Company 201 - Biologically compatible polymers that provide non-surgical regenerative therapies for treating chronic and acute episodes of pain
• Company 202 - The only device-based therapy, offering low-cost and non-invasive treatment for a wide range of antenatal conditions; thereby promising to prevent preterm birth
• Company 203 - The first miniature and highly accurate guide for brain surgery that is fully MRI-compatible and gives the possibility to perform simultaneous bilateral procedures, in addition to being easy-to-use and cost-effective
• Company 204 - A hand-held device with a touch-screen interface that identifies a patient's preferred language and then collects his/her information, medical history, symptoms, and complaints, which are then summarized into the caregiver's language and can be accessed on the device/through a facility's electronic health records (EHR) system
• Company 205 - Innovative single-use surgical retractors designed to manage all MIS exposure needs in gynecological, digestive, visceral, and vascular surgery
• Company 206 - Small, discrete, and disposable device to reduce food intake
• Company 207 - Cartilage repair using cell therapy - true, 100% hyaline cartilage tissue, in a single procedure, using an off-the-shelf product
• Company 208 - X-ray light valve device for use in conjunction with mammography screening and future imaging modalities
• Company 209 - Genetic test for expectant mothers that detects spina bifida
• Company 210 - Hand-held, disposable device that transdermally removes spider and reticular veins without a sclerotherapy agent
• Company 211 - Needle-free silicone patch for vaccine delivery
• Company 212 - Next-generation PCR system that can provide absolute quantification of nucleic acid molecules, at higher resolution and lower target levels than the current standard, thereby identifying diseases earlier in progression
• Company 213 - ClearRing is a minimally invasive prostatic reshaping implant for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
• Company 214 - Immediate detection and identification of bacteria in bodily fluids through optical spectroscopy with low quantities of material without bacteria culturing
• Company 215 - Temporary implantable ventricular assist device (VAD) that wraps around the heart and squeezes it to help pump blood
• Company 216 - Non-invasive nitric oxide gas (gNO) technology and iontophoresis drug delivery for treating diseases of the skin and nails
• Company 217 - Immunomagnetic cell capture system which isolates and removes pathogens directly from the blood in under 30 minutes
• Company 218 - Synthetic 3D extracellular matrices to support tissue growth for use in a wide range of regenerative medicine
• Company 219 - Small molecule plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME)
• Company 220 - Prefilled, easy-to-carry epinephrine auto-injection device for people with severe allergies
• Company 221 - Micro-needle skin patch for delivery of the influenza vaccine
• Company 222 - Hand-held device that sublingually monitors changes in carbon dioxide (CO2) levels for the prevention of septic shock
• Company 223 - Minimally invasive memory polymer devices for use in peripheral vascular, non-vascular, and neurovascular applications
• Company 224 - Energy-based thermal surgery device that provides better soft tissue cutting and coagulation
• Company 225 - Aerosol-based inhaled insulin delivery device
• Company 226 - A light-based medical device in the form of an LED patch with a proprietary, optimized formulation of light which triggers local, controllable, and safe Nitric Oxide (NO) production to treat diseases triggered by underlying vascular dysfunction
• Company 227 - Implantable, wireless, intracranial pressure monitor for use in patients with tumors, prior strokes, and traumatic brain injuries (TBI)
• Company 228 - Self-expanding, fully removable, temporary inferior vena cava (IVC) filter used in conjunction with the placement of a central line for the prevention of pulmonary embolism
• Company 229 - The BNX(TM) (Beacon-Needle-eXchange) needle delivery system for use in gastrointestinal endoscopic procedures including: Endoscopic Ultrasound (EUS), Endoscopic Bronchial Ultrasound (EBUS), and Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
• Company 230 - Low-cost mobile device and software that adapts smartphones into ECG machines
• Company 231 - Next-generation prefilled drug delivery devices, including prefilled syringes, auto-injectors, and IV systems, offering improved product performance at lower costs
• Company 232 - Electrophysiological mapping device for the treatment of complex cardiac arrhythmias
• Company 233 - Hand-held, non-contact vein illumination device for imaging veins just below the surface of the skin
• Company 234 - Miniaturized, continuously adaptable, left ventricular assist device (LVAD) for the treatment of heart failure
• Company 235 - Drugs to treat breast and other cancers by targeting cancer stem cells
• Company 236 - Real-time vital signs monitoring with data collected from earbuds and streamed wirelessly to mobile devices or the web for viewing
• Company 237 - Drug therapy for the treatment of rare diseases such as hereditary inclusion body myopathy (HIBM)
• Company 238 - Compounds for oncology indications, including: 1-the prevention of A) chemotherapy-induced nausea and vomiting (CINV), B) post-operative nausea and vomiting (PONV), and C) chronic cough and 2-treatment for patients with non-small cell lung cancer (NSCLC) whose tumors express an Anaplastic Lymphoma Kinase (ALK) fusion protein
• Company 239 - Portable, self-contained system for the precise minimally invasive removal of diseased tissue, to restore natural tendon and soft tissue function in the elbow, knee, ankle, foot, and shoulder
• Company 240 - Thermal pulsation system for effective, in-office treatment of evaporative dry eye
• Company 241 - Non-invasive neuromodulation device that exposes the brain to an oscillating magnetic field, for the treatment of psychiatric and neurological disorders such as major depressive disorder and bipolar depression
• Company 242 - Real-time orthopedic surgery imaging system that will save valuable time for surgeons and hospitals, while improving surgery accuracy and patient safety
• Company 243 - An interactive, computer-assisted system utilizing image-guided robotics to enhance the quality of hair follicle harvesting during hair restoration surgery
• Company 244 - Wireless, non-invasive, and portable brainwave recording device for convenient at-home sleep monitoring and analysis to: 1-offer insight into the diagnosis and treatment of conditions such as Alzheimer's, autism, cancer, epilepsy, depression, and schizophrenia and 2-reveal how drugs affect the brain
• Company 245 - Implantable drug delivery device using nanochannel-based chip to control/modulate release
• Company 246 - Non-invasive device to alleviate the symptoms of subjective tinnitus that synchronously presents sound using headphones and tactile representations to an intra-oral array on the tongue
• Company 247 - A family of single-use devices that provide quantitative pressure measurements, while alleviating doubt and uncertainty during common medical procedures such as central line insertions, spinal taps, and epidurals
• Company 248 - Ozone injection system for multiple spinal applications, including herniated disc, to eliminate the need for multiple steroid injections and/or a surgical discectomy
• Company 249 - Bone anchorage technology for use in spine, trauma, and general orthopedics
• Company 250 - Non-systemically absorbed compounds for the treatment of diabetes and obesity, as an alternative to gastric bypass surgery
• Company 251 - Diagnostic tests that leverage the ability to extract clinically relevant information from maternal blood, including a non-invasive prenatal test to diagnose specific genetic and other inherited disorders
• Company 252 - Regenerative stem cell therapy to treat heart failure (HF), acute myocardial infarction (MI), angina, peripheral artery disease (PAD), and hard-to-heal wounds including burns, diabetic foot ulcers, venous stasis ulcers, and pressure ulcers
• Company 253 - A non-invasive hand-held system for accurately measuring circulating blood volume in real-time, to quickly identify and treat shock
• Company 254 - Device used to safely deliver epidural anesthesia during childbirth and other procedures
• Company 255 - Implantable neurostimulation device for the treatment of obstructive sleep apnea (OSA)
• Company 256 - Pressurized olfactory drug delivery device to bypass the blood brain barrier and deliver greater pharmaceutical concentrations
• Company 257 - Pancreatic islet cell transplantation as a potential cure for Type I diabetes
• Company 258 - Liver dialysis system that removes protein-bound toxins plus water-soluble toxins from blood and is more effective and cost-efficient than currently available therapies
• Company 259 - System that is capable of simultaneous quantitative and independent determination of up to 100 biomarkers in individual cells, not possible with existing technologies, for early disease diagnosis and monitoring of treatment efficacy
• Company 260 - Molecular testing that analyzes gene expression in airway epithelial cells to detect early signs of lung cancer
• Company 261 - Biocompatible surgical mesh with high tensile stiffness and strength, similar to native tendon, that is sutured over torn or degenerative tissue as a reinforcement to surgical repair to allow for rapid tissue in-growth
• Company 262 - Next-generation quantitative angiography
• Company 263 - A "smart shirt" that can count a patient's heartbeats through its sensors, record a medical quality electrocardiogram (ECG), and detect the respiration rate, body temperature, and position of the patient (standing, walking, lying, asleep, or fallen)
• Company 264 - Soft, flexible devices with tissue-like characteristics that can be used for health and wellness, cardiology, and neurology to make surgical diagnosis and treatment easier - based on a new generation of thin, conformal electronics technology that endures bending, twisting, and stretching without sacrificing performance
• Company 265 - Technology that manages the exit sites of central venous catheters by promoting the formation of a biological seal around the catheter that blocks the route for bacteria
• Company 266 - A non-invasive, optical brain monitor for monitoring hypnosis (depth of anesthesia) and level of sedation via direct non-invasive measurement of changes in deoxyhemoglobin (deoxy Hb)
• Company 267 - A disposable skin patch that provides diabetics with a painless, BLOODLESS, easy-to-use, and rapid method for monitoring glucose levels
• Company 268 - Interwoven biopolymer 3D-oriented matrices that more accurately mimic natural extra cellular matrix (ECM) for use in cell and tissue engineering applications
• Company 269 - Revolutionary HyperQ technology based on advanced signal processing of the high frequency ECG signal, enabling more accurate results in the initial diagnosis of coronary artery disease (CAD)
• Company 270 - Optical Ultrasound Tomography(R) (OUT) identifies brain injuries, brain hematomas, malignant breast cancers, and Inflammatory Breast Cancer safely and quickly and displays 3D images in "real time" and can transmit the images to waiting hospitals and surgeons. The cameras are lightweight and portable, and can be mounted on a bedside providing continuous monitoring of hemorrhages and the flow of blood. They can be used in an ambulance, on the battlefield, on the Little League field, and in the ER.
• Company 271 - A scalable molecular diagnostic chip platform that will allow for the diagnosis of diseases in five minutes as well as in-home monitoring of conditions such as: profound venous thrombosis, embolisms, and myocardial infarctions (MI)
• Company 272 - Transcutaneous vagus nerve stimulation to treat patients suffering from drug-resistant epilepsy or other difficult-to-treat neurological and psychiatric disorders
• Company 273 - Implantable device consisting of a series of miniature magnetic beads, linked together to form a "bracelet" around the Lower Esophageal Sphincter (LES) for the treatment of gastroesophageal reflux disease (GERD)
• Company 274 - Wireless 3G cellular-enabled blood glucose meter that instantly transmits glucose values to a care-management server and provides instant feedback and coaching to patients with diabetes
• Company 275 - Accurate, ultra-low-cost whole genome sequencing by way of a simple, single-molecule detection process
• Company 276 - Drug therapy focusing on the carotid body for the treatment of sleep-related breathing disorders
• Company 277 - Deep brain stimulation probe technology for advanced and personalized treatment of degenerative or functional brain disorders, such as Parkinson's disease and dystonia
• Company 278 - Versatile, easy-to-use, accurate, and cost effective aorto-ostial stent positioning system to facilitate precise stent implantation in coronary and renal arteries
• Company 279 - Device that increases the size of skin grafts without the use of chemicals, biologics, or enzymes
• Company 280 - Immediate and permanent contraception implant for women to use as an alternative to surgical tubal ligation
• Company 281 - Tissue expander technology that allows both diagnostic and therapeutic capabilities never before available during tissue expansion
• Company 282 - Tendon repair device that utilizes a simple and familiar technique to ingeniously join tissue together, with broad applications across a range of surgical sub-specialties
• Company 283 - Novel solutions for wound closure
• Company 284 - Sternal closure system that maintains rigid fixation of the sternum in multiple directions of force and eliminates the common causes of sternal dehiscence
• Company 285 - Bioseparation technology, for use outside of the research lab, with broad applications from molecular diagnostics to transplant therapies
• Company 286 - Non-invasive system for the treatment of acute ischemic stroke and other vascular disorders using externally applied ultrasound that can be rapidly and easily deployed by virtually any emergency room staff
• Company 287 - Genomics-based diagnostic tests for obstructive coronary artery disease (CAD), cardiac arrhythmias, and heart failure (HF)
• Company 288 - Nicotinic receptor agonist compounds for the treatment of asthma and other inflammatory respiratory and non-respiratory diseases
• Company 289 - Femoral vascular access catheter that uses a longer and shallower angle arteriotomy, providing better site closure WITHOUT vascular closure implants
• Company 290 - Surgical instruments, medical lasers, and other medical devices
• Company 291 - KeyHole Cup(R) is designed to provide a safer and efficient entry into the abdominal cavity during laparoscopic surgery. It allows for a more rapid insufflation than standard techniques, mitigating associated risks.
• Company 292 - Cost-effective lab-on-a-chip system that anyone can use to get laboratory quality results in any location, within minutes, and with minimal training
• Company 293 - ImagistxProstate(R), a breakthrough prostate imaging technology providing a diagnostic tool to identify prostate cancer via its 21 MhZ center frequency, 512 element array, and 3D ultrasound capabilities
• Company 294 - Proven patented technology platform that rapidly and accurately measures oxidative stress and oxidizability in blood and other biologic fluids, with multiple diagnostic applications
• Company 295 - Real-time pathology solution for cancer surgical guide, with microchip-based in vivo imaging systems
• Company 296 - A disposable, flexible conduit that provides a protective channel through which an endoscope is inserted for sinus surgery, to keep the introduction site open throughout the course of the procedure, thereby minimizing trauma along the nasal passageway
• Company 297 - Novel bilateral brain monitor with independent hemisphere indexing for the direct measurement of the effects of anesthetics and sedatives, which allows for patient-specific dosing
• Company 298 - Intelligent continuous glucose monitoring device utilizing recent innovations in microneedle and bluetooth technology, to provide a more accurate and pain-free method than what current devices offer
• Company 299 - Professional and home use devices for automated bladder assessment incorporating a novel, extremely compact, 3D ultrasound scan head and embedded image processing technology
• Company 300 - Ultrasound-based molecular imaging agents that can be used to: 1-diagnose and stage disease, 2-monitor response to therapy in the pharmaceutical research setting, and 3-elucidate the biology of disease processes in the basic science setting
• Company 301 - Portable brain sensing system to rapidly diagnose ischemic stroke at point-of-care; other indications include identification of brain trauma and cerebrovascular abnormalities and continuous monitoring of stroke patients
• Company 302 - Minimally invasive system for decompressing pinched nerves in the spine, based on highly maneuverable tools and a precise tissue-removal mechanism
• Company 303 - The Vortex ZDS(TM) catheter reduces Catheter Associated Urinary Tract Infections (CAUTIs) by at least 50% to replace Foley catheter as the indwelling urinary catheter of choice
• Company 304 - Non-invasive real-time diagnostic tools for early detection, prevention, and management of Acute Kidney Injury (AKI) in critical care environments
• Company 305 - A unique permanent injectable bulking agent for the endoscopic treatment of GERD (chronic heartburn)
• Company 306 - Therapies for the treatment of acute wounds, chronic wounds, scarring, abnormal scarring, inflammation and pain, fibrosis, surgical adhesions, and orthopedic procedures
• Company 307 - A Percutaneous Tracheostomy (PT) system that simplifies the traditional PT technique to be used by more physicians OUTSIDE of the Operating Room (OR) and in faster times than current devices
• Company 308 - Mammary Aspirate Specimen Cytology Test (MASCT System(TM)) that collects a small amount of nipple aspirate fluid (NAF) in 10 minutes, using no radiation and is painless
• Company 309 - Cardiac mapping catheters to analyze electrical heart activity for the diagnosis of cardiac arrhythmias
• Company 310 - Thermal infusion fluid warmer device that enables surgeons to manage and warm up to five fluids at once
• Company 311 - Next-generation insulin analogs for both the rapid-acting and long-acting insulin markets
• Company 312 - New embolotherapy catheter that minimizes reflux when administering medication
• Company 313 - Non-surgical, removable hearing device that transmits sound through the teeth for the treatment of single-sided deafness
• Company 314 - Medical devices for the treatment of neurovascular conditions
• Company 315 - Next generation X-ray scintillator device that provides high resolution imaging
• Company 316 - Permeable, micro-porous, flexible, and user-friendly implants in tubular or patch shape for bone reconstruction and fracture repair in surgical procedures
• Company 317 - Flexible endoscopy and endoluminal surgery device
• Company 318 - Drug therapy for the treatment of inner and middle ear disorders
• Company 319 - In vivo optical imaging devices for real-time diagnosis in a broad range of applications
• Company 320 - Headset that detects and records brainwaves for the diagnosis of Alzheimer's disease and other neurological disorders
• Company 321 - Drug therapy by way of modulating the N-methyl-D-aspartic acid receptor for the treatment of depression and other central nervous system disorders
• Company 322 - Smart-phone based ultrasound imaging system
• Company 323 - Minimally invasive devices using radiofrequency (RF) energy for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence (FI)
• Company 324 - Portable, non-invasive device designed to offer transcutaneous pulsed electro-magnetic field stimulation therapy for treating post-operative pain and inflammation in superficial soft tissue
• Company 325 - Implantable electronic gastric stimulation device for the treatment of obesity
• Company 326 - High-intensity ultrasound energy for non-invasive reduction of arterial plaque
• Company 327 - Catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels
• Company 328 - The VortxRX delivers non-invasive Histotripsy with image guidance to treat benign prostatic hyperplasia (BPH). Histotripsy homogenizes prostatic tissue non-thermally as it is monitored in real time with ultrasound imaging.
• Company 329 - Robotic and manual endoscopy devices for increased ergonomics during laparoscopic surgery
• Company 330 - Eye-tracking device for earlier diagnosis of Parkinson's disease and other neurological diseases
• Company 331 - Device that uses localized vibrations to reduce pain during injections
• Company 332 - The first non-invasive, prep-free imaging test for colon cancer
• Company 333 - Biologically-active plastic surgical patch for rotator cuff and tendon injuries, designed to promote healing and formation of new bone
• Company 334 - Catheter-based drug delivery system for the treatment of vascular disease and restenosis
• Company 335 - Anti-infectives for the treatment of severe infectious diseases
• Company 336 - Device for the intraocular delivery of photoactive nanoparticles for the treatment of retinitis pigmentosa, macular degeneration, and diabetic retinopathy
• Company 337 - Venous stenting device and ablation technology for the treatment of chronic venous disease
• Company 338 - Devices that facilitate minimally invasive access to a beating human heart and the delivery of therapeutic options intended to treat complex cardiovascular diseases
• Company 339 - Customized Sound Therapy (CST) system for tinnitus therapy
• Company 340 - Artificial sphincter device for use in ostomy and stoma care
• Company 341 - Microcatheters for treating and preventing acute ischemic stroke
• Company 342 - Spinal probe that uses radiofrequency (RF) ablation on nerves thought to be the cause of chronic back pain
• Company 343 - Disposable device for the prevention of catheter-related infections from hemodialysis
• Company 344 - Single-use needle-free injection system for liquid medications
• Company 345 - Non-invasive Auto-Targeting Neurostimulation (ATN) device for high-stimulation pinpoint treatment of lower back pain
• Company 346 - Portable, patch-based device that delivers "slow release" ultrasound to treat localized pain and induce soft tissue healing
• Company 347 - Shape memory implants that restore motion and eliminate pain for patients requiring soft tissue repair, fracture fixation, or joint fusion
• Company 348 - Removable adhesion barriers for spinal, tendon, and nerve-related surgery to reduce post-operative scarring, pain, numbness, muscles weakness or limited motion
• Company 349 - Orthopedic implants for limb lengthening/correction/reconstruction
• Company 350 - Neurocatheter for the removal of blood clots in the brain
• Company 351 - Portable/mobile nuclear cardiology imaging system
• Company 352 - The first and only wire-independent embolic protection that uses any single guide wire of choice for the entire procedure and seamlessly integrates with standard workflow
• Company 353 - Single-use devices that will address epicardial access, protection, and treatment facilitating the electrophysiologist's ability to perform cardiac ablations more efficiently and with a higher degree of safety and effectiveness
• Company 354 - Irrigation devices for improved visualization during upper and lower gastrointestinal (GI) procedures
• Company 355 - DNA-testing platform that enables results from a wide variety of gene signatures to be delivered quickly, simply, and cost-effectively at the point-of-care (POC) within an hour
• Company 356 - A market leading non-invasive hypoglycemic symptom detection device that protects diabetics from emergency low-blood sugar events. Hypoglycemia healthcare costs average $7,000 per episode and can result in death to the patient.
• Company 357 - High-stability, short-length expandable implants that eliminate the need for complex bone augmentation - shortening overall time to implantation and significantly lowering treatment costs
• Company 358 - System that cools cerebral spinal fluid to reduce injuries associated with spinal and cerebral ischemia
• Company 359 - Infection control technology that does something no other product can - protect and disinfect BOTH the needleless injection site and the end of the IV tubing male luer
• Company 360 - Biodegradable, inflatable balloon device which separates healthy organs from adjacent tumors receiving radiation therapy
• Company 361 - The first passive fetal movement monitor (detector, analyzer, and data logger) for expectant mothers to use at home
• Company 362 - A minimally invasive implantable pulse generator (IPG) to treat obese and type II diabetics by applying electrical stimulation to the duodenum
• Company 363 - Implantable artificial pancreas for the treatment of patients with Type I & Type II diabetes
• Company 364 - Non-invasive hand-held device that detects abnormal heart sounds and uses a smart-phone interface for the diagnosis of coronary artery disease (CAD)
• Company 365 - Aerosol technology which efficiently delivers therapeutics into the abdominal cavity of patients during surgery to combat post-surgical complications such as pain and adhesions
• Company 366 - Self-powered miniature pacemaker and leadless electrodes implantable through minimally invasive procedures; used to treat arrhythmia
• Company 367 - Innovative sutureless technology for blood vessel anastomosis
• Company 368 - Incubator with 12 fully owned portfolio companies and 20+ fully owned pipeline technologies, driven by unmet market need
• Company 369 - The only device enabling simultaneous, non-invasive, and continuous measurement of blood flow and oxygen saturation
• Company 370 - Functional optical imaging technology for the early diagnosis and guided treatment of blinding retinal diseases and diseases of other organs of the body; it is the only optical imaging approach that allows visualization of the capillaries, non-invasively (without any contrast agent)
• Company 371 - A point-of-care diagnostic system for rapid, sensitive, quantitative biomarker panels that delivers laboratory-quality results in a clinic or doctor's office, within minutes
• Company 372 - Next-generation, cost-effective ophthalmic implants made from STAR(R) biomaterial that will help patients suffering from glaucoma and corneal blindness
• Company 373 - Continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of tight glycemic control (TGC) in the intensive care unit (ICU)
• Company 374 - Non-invasive devices for continuous real-time evaluation of hemodynamic changes
• Company 375 - Grafts for small diameter (less than 5mm) artificial blood vessels in both peripheral and coronary applications
• Company 376 - 1-Deep brain stimulator (DBS) to treat movement disorders, 2-A hybrid auditory implant (HAI) to treat severe hearing loss
• Company 377 - Innovative hydrogel technology for tissue repair including cartilage, bone, and dermal of the knee, wrist, elbow, shoulder, and ankle
• Company 378 - An ophthalmic device company delivering Navigated Retinal Laser Therapy to address the unmet need for durable and cost-effective outcomes in the treatment of major vision-threatening retina diseases, primarily caused by a complication of diabetes
• Company 379 - Best-in-class platform to optimize genes and proteins in human therapeutics
• Company 380 - Cloud/web-based medical imaging data management software and infrastructure as services - to replace picture archiving communication system (PACS) at a significantly reduced cost
• Company 381 - Incubator with over 100 highly novel medical technology inventions spanning most medical markets
• Company 382 - The only minimally invasive cure for spinal stenosis that maintains the natural dynamics of the spine
• Company 383 - Technology to embed Nitric Oxide (NO), part of the innate immune system, into polymer medical devices to make them antimicrobial without the issues of antibiotic resistance
• Company 384 - Minimally invasive catheter-based system that safely, rapidly, and effectively removes thrombus and restores blood flow in the peripheral vasculature utilizing ultrasound energy to destroy clots, without harming adjacent healthy tissue or generating dangerous emboli
• Company 385 - 1-Effective cryosurgical tool that is simple and safe to use without cryogenic gasses or liquids for all medical office skin lesion removal needs, 2-Cervical freeze attachment for gynecology use, 3-Third-generation technology to accommodate cryosurgical treatments for prostate, liver & renal cancers and cardiac aberrant foci ablation
• Company 386 - Remote (wireless) continuous EEG (cEEG) brain monitoring of critical care patients that significantly reduces mortality rates, improves patient outcomes, and saves millions of dollars in patient care expense
• Company 387 - Atherosclerotic plaque dissolution through chemical means for treating occlusive and non-occlusive atherosclerotic disease that may reduce the need for permanent implants like drug-eluting stents (DES), while also potentially addressing plaque instability
• Company 388 - Revolutionary raman-spectroscopy based platform technology licensed from the BC Cancer Agency to aid in the early detection of cancer
• Company 389 - 1-Non-invasive in vitro diagnostic (IVD) blood test for the detection and/or monitoring of 14 different types of cancer, 2-Combination Immunogene Therapy (CIT) technology that could lead to a vaccine or possibly treat those already diagnosed with cancer
• Company 390 - A low-cost, clip-on eye-piece for mobile phones that mimics and replaces the expensive laser-based Shack-Hartmann wavefront aberrometers to diagnose the most common refractive eye disorders: myopia (nearsightedness), hypermetropia (farsightedness), astigmatism, and presbyopia (age-related visual impairment)
• Company 391 - Non-invasive, rapid assessment of dP/dt in Cardiac Resynchronization Therapy (CRT) for lead placement, lead optimization, and monitoring
• Company 392 - Unique, patented, activated collagen, CellerateRX(R) for the expanding diabetes and greater wound care markets
• Company 393 - A medical implant surface technology company focused on the design and manufacturing of proprietary and cellular-friendly interbody fusion devices for the spine
• Company 394 - Anatomically appropriate orthopedic implants, unique instrumentation, and biologics for pediatric and small stature patients
• Company 395 - Proprietary medical devices and patient interfaces for the enhancement of patient safety through capnography monitoring
• Company 396 - 1-Adult stem cell collection and storage, 2-VSEL(TM) (very small embryonic-like) stem cells for tissue regeneration, 3-Contract cell manufacturing for clients around the world, Progenitor Cell Therapy, 4-Therapeutics such as a T-cell regulatory technology to treat disorders of the immune system, 5-A wound healing technology that uses autologous bone marrow-derived stem cells, 6-An autologous bone marrow-derived cell line selected to treat damaged heart muscle following AMI
• Company 397 - A business and technology research & development platform, dedicated to delivering innovative solutions for the musculoskeletal disorders industry
• Company 398 - Ellanse, the first dermal filler family offering a complete customized solution in medical aesthetics
• Company 399 - A Peripheral Nerve Stimulation (PNS) system for patients suffering from severe, intractable pain
• Company 400 - Portable, disposable, non-powered suction device for negative pressure wound therapy (NPWT)
• Company 401 - Device that prepares 10 million micro-droplets per hour for use in drug discovery, genomics, molecular epidemiology, and proteomics
• Company 402 - Non-invasive imaging system for the early detection of pre-cancerous tissue and to guide early treatment intervention
• Company 403 - A handheld breath analyzer for the measurement of fat metabolism
• Company 404 - Portable pediatric vision-screening device for early diagnosis of serious vision abnormalities
• Company 405 - Minimially invasive percutaneous implantable cardioverter defibrillator (PICD) for the treatment of cardiac arrhythmias
• Company 406 - A non-invasive, automatic analyzer that uses measurements of sweat gland activity to determine whether a patient is at risk for diabetes
• Company 407 - Compact, home-based device for male fertility assessment
• Company 408 - Device for the early detection, assessment, and monitoring of mild perceptual impairment (MPI), an early indicator of mild cognitive impairment
• Company 409 - Device providing sustained intravesical drug delivery for the treatment of Overactive Bladder (OAB), Interstitial Cystitis (IC), and other bladder conditions
• Company 410 - Percutaneously-inserted interspinous process fusion cages that provide for stabilization of the spine
• Company 411 - Implantable neurostimulation system for the treatment of obstructive sleep apnea (OSA)
• Company 412 - Physical and chemical resurfacing of orthopedic implants and stents which allows for drug elution without the use of a binding polymer
• Company 413 - Wireless, implantable heart device that allows Congestive Heart Failure (CHF) patients to monitor data using a handheld instrument
• Company 414 - Percutaneous vertebral augmentation (PVA) system for controlling bone cement delivery and leakage during spinal surgery
• Company 415 - Remotely controlled percutaneous catheter system for use in a wide range of interventional applications
• Company 416 - Novel and clinically-validated percutaneous approach for the treatment of functional mitral regurgitation in the heart failure population
• Company 417 - Sutureless, anastomotic connectors to provide a controlled method of joining vessels
• Company 418 - Minimally invasive orthopedic device for the treatment of hip pain
• Company 419 - Handheld device for monitoring chronic disease home-care patients using a single drop of blood
• Company 420 - 1-Novel 510(k)-cleared XCOIL(TM) mechanical thrombectomy device initially targeting DVT and stroke patients and 2-Novel 510(k)-cleared EViTAR(TM) double-lumen, coaxial neurocatheters for intracranial delivery of small molecules, biologics, stem cells/gene-based therapies, and smart sensor enhancements
• Company 421 - Microwave-based soft tissue ablation
• Company 422 - Implantable device to treat epilepsy by anticipating seizures and delivering intracranial drugs
• Company 423 - Injectable, synthetic bone subsitutes
• Company 424 - Device that delivers iron transdermally for patients with iron-deficiency anemia
• Company 425 - Implantable pacing and defibrillation device that detects the early onset of atrial fibrillation and chronic heart failure and delivers targeted medications
• Company 426 - Device for dry powder pulmonary delivery to treat patients with Parkinson's disease
• Company 427 - A thrombectomy catheter for peripheral artery disease (PAD) that features a rotating, extending tip
• Company 428 - A unique, non-invasive tool for the analysis of muscle function to assist in the evaluation and treatment of neck and back injuries and illnesses
• Company 429 - Vital signs monitoring device for use as an early congestive heart failure (CHF) crisis indicator at home, to avoid acute/expensive hospitalizations
• Company 430 - Novel bioresorbable regenerative scaffolds that provide 3D architecture for enhanced tissue repair
• Company 431 - Novel implantable ultrasound flow-measuring devices with flow data wirelessly transmitted from within the body
• Company 432 - Technology for nurses/pharmacy technicians/emergency responders to more safely and effectively vaccinate the public in the event of a biological or viral pandemic
• Company 433 - Modular, powered, proprietary articulating technology for endoscopes and laparoscopes, enabling surgical safety, flexibility, and procedural innovations
• Company 434 - Medical image viewing solution that enables physicians to access/view critical patient images/information from anywhere, without compromising the security/privacy of the data
• Company 435 - An elegant, user-friendly alternative to traditional eye dropper bottles that will allow multi-dose of preservative-free ophthalmic formulations
• Company 436 - Device-based technology with an anti-inflammatory therapeutic platform to appreciably widen the present window of treatment for ischemic stroke to 12-18 hours
• Company 437 - Novel micro-texture pattern applied to surfaces and medical devices to inhibit bacterial colonization and reduce infection by producing an unsuitable environment for growth; this no-kill approach without the use of biocides does not contribute to antimicrobial resistance
• Company 438 - StimBrace addresses osteoarthritic knee pain by intelligently strengthening leg muscles to stabilize and brace the knee during real-world use
• Company 439 - Image-guided interventional endoscopy products
• Company 440 - An expandable, funnel-shaped cannula for the removal of intravascular material during extracorporeal circulation
• Company 441 - Teraherz-based, real-time, video-rate imaging system
• Company 442 - A wearable product that uses Touch Activated Phlebotomy (TAP) technology to reduce the inconvenience of blood sampling and facilitate simpler diagnoses
• Company 443 - Radiofrequency (RF)-based detection systems to reduce the risk of retained surgical sponges
• Company 444 - A removable surgical implant to improve vision loss resulting from presbyopia
• Company 445 - A minimally invasive, green, laser-based technology for the treatment of benign prostatic hyperplasia (BPH), as an alternative to traditional TURP surgery
• Company 446 - An artificial silicone microchip, which stimulates retinal cones and rods to restore retinal function
• Company 447 - An automated, continuous glucose monitor for bedside use in intensive and critical care
• Company 448 - A small, injectable ophthalmic implant containing multiple, laser-activated reservoirs designed for the on-demand, physician-controlled release of ocular drug therapies to the back of the eye
• Company 449 - A non-invasive, portable device that treats glioblastomas with electrical fields
• Company 450 - A bionic retina designed to restore sight to millions blinded by retinal degenerative diseases
• Company 451 - 1-Biochemical sensing technologies for continuous glucose monitoring and 2-Drug-delivery devices for osteoporosis management
• Company 452 - Less invasive technologies and a more effective option for Primary Open Angle Glaucoma patients
• Company 453 - 1-A long-term cardiac rhythm monitor and 2-A disposable electrocardiography (ECG) monitor for use for up to 30 days
• Company 454 - Devices for arthroscopy, hip, knee, and spine surgery, in addition to radiofrequency identification (RFID) tracking technology
• Company 455 - A percutaneous implant for mitral valve repair
• Company 456 - Capsule-based hydrogels to reduce food intake in obese patients
• Company 457 - Novel, implantable cardiovascular device
• Company 458 - Whole-body imaging technology for orthopedic applications
• Company 459 - Advanced surgical devices for ear, nose, and throat (ENT) surgery
• Company 460 - 3D full-breast ultrasound imaging device for the detection of benign or malignant masses
• Company 461 - Radiofrequency (RF)-based device for the treatment of congestive heart failure (CHF)
• Company 462 - A wireless, touch-screen insulin pump featuring a blood glucose meter, food library, and an activity monitor
• Company 463 - Synthetic cartilage technology for joint repair
• Company 464 - A vertebral restoration system that uses spine-specific osteogenic biomaterials to restore vertebral stability
• Company 465 - Advanced long-term hemodialysis and peritoneal dialysis catheters
• Company 466 - Portable and advanced point-of-care diagnostics equipment
• Company 467 - Endovascular device targeting the treatment of abdominal aortic aneurysms (AAAs)
• Company 468 - A wireless, remote-controlled unit targeting tissue expansion for breast reconstruction
• Company 469 - User-friendly, simple, and needle-free transdermal delivery system that can deliver a broad range of compounds, including: peptides, proteins, small molecules, and vaccines
• Company 470 - Brachytherapy device for gynecological cancers
• Company 471 - Ophthalmic implant for improved vision in patients with end-stage age-related macular degeneration (AMD)
• Company 472 - Small, disposable, discreet, and very convenient alternative to CPAP for obstructive sleep apnea (OSA) patients
• Company 473 - A wearable, battery-operated, bionic leg - used as a robotic aid during therapy sessions, until the patient recovers their gait so they can walk/continue to improve without it
• Company 474 - Surgical films, meshes, sutures, and other products constructed from a new class of absorbable biomaterials
• Company 475 - Advanced sealants and anti-adhesion agents for use in vascular and general surgery
• Company 476 - Devices to treat diseases and injuries of the foot and ankle, resulting in faster ambulation, superior cosmesis, and less pain
• Company 477 - Benchtop-based positron emission tomography (PET) imaging system
• Company 478 - System that features an intramedullary implant for fusion or fixation of the sacroiliac (SI) joint using a small incision
• Company 479 - Magnetic technology used to destroy blood clots
• Company 480 - P.L.E.A.S.E.(R) (Precise Laser Epidermal System) - a novel transdermal delivery device for high molecular weight drugs, that can be used by medical personnel or the patient
• Company 481 - Technology platform that uses physical vapor deposition, thin film technology, and thin film metals to produce stents and other implants that feature greater biocompatibility
• Company 482 - Laparoscopic devices for single-port surgery and natural orifice transluminal endoscopic surgery (NOTES)
• Company 483 - Device that stimulates the urinary bladder electrically in order to modulate key renal functions, thus, breaking the vicious cycle of cardio-renal interaction in congestive heart failure (CHF) patients
• Company 484 - Endometrial ablation system that uses a low-profile insertion diameter, automatic power settings, an atraumatic tip, and an ergonomic handle, to provide therapy quickly and comprehensively
• Company 485 - A two-step treatment for ischemic stroke patients that provides rapid reperfusion as well clot capture and retrieval
• Company 486 - Transcatheter cardiac valve replacement technology
• Company 487 - Laser system that uses an integrated ocular measurement technology and short-pulse laser to perform surgical incisions for refractive cataract surgery
• Company 488 - Advanced surgical field illumination technologies to improve surgeon visualization and reduce surgeon fatigue in less invasive surgery
• Company 489 - Home dialysis system that integrates multiple, advanced micro-technologies
• Company 490 - Deep brain stimulation (DBS) technology for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI)
• Company 491 - External fixation system that uses specialty clamps to: reduce the construct weight, enable greater flexibility for the surgeon, and reduce operating times
• Company 492 - Ablation system that uses a specialty catheter to deliver low-pressure liquid nitrogen for tissue ablation during endoscopy
• Company 493 - Disposable device to provide fast, objective measurement of vaginal cervical length, which assists in the determination of whether the patient is undergoing preterm labor
• Company 494 - Optical sensing technology for non-invasive pH monitoring of stored platelets
• Company 495 - Software allowing physicians to remotely monitor vital signs using smartphones and hybrid tablet devices such as the iPhone, BlackBerry, Android, Windows Mobile devices, and iPad/Android-based tablets
• Company 496 - Patch-based technology that delivers a weekly, low-dose contraceptive to women
• Company 497 - Integrated system that monitors the activity of patients and caregivers in long-term care environments and features a proprietary fiberoptic sensor to detect patient movement, thereby detecting falls and helping to prevent pressure ulcers
• Company 498 - Remotely-operated, in vivo, miniature robotic products for laparoscopic surgery
• Company 499 - Angioplasty stenting system intended to reduce procedure times
• Company 500 - Integrated system comprising reusable and disposable devices, components, and software to enable magnetic resonance imaging (MRI)-guided neurological procedures
• Company 501 - Devices used to assist in the introduction and advancement of endoscopes in the upper and lower gastrointestinal (GI) tract
• Company 502 - Wireless platform for continuous monitoring of vital signs
• Company 503 - 510(k) cleared device using acoustic reflectometry to continuously monitor breathing tubes for placement, movement, and obstruction, enabling adverse event prevention
• Company 504 - Platform of technologies used to lower intraocular pressure (IOP) for glaucoma patients, including the Gold Shunt implant, the 790 laser for trabeculoplasty, and a sensor to continuously monitor IOP
• Company 505 - Paddle that measures the mechanical properties of breast tissue during mammography, reducing pain and discomfort
• Company 506 - Implantable neurostimulation device to treat inflammation
• Company 507 - Repositionable transcatheter aortic valve replacement system
• Company 508 - Technology to treat cardiac arrhythmias
• Company 509 - Diagnostic system for hematology and HIV-immune monitoring in developing countries
• Company 510 - Bronchoscopically-placed nitinol coil for lung volume reduction
• Company 511 - Controlled electrical pulses delivered to nerve clusters to improve swallowing function and control in patients with acute dysphagia
• Company 512 - Hand-held device intended for use in facial rejuvenation
• Company 513 - Hand-held device that deactivates the axillary glands using electromagnetic energy, thereby eliminating the problem of massive underarm sweating
• Company 514 - Hand-held point-of-care and home-based testing devices that measure blood viscosity for patients taking Warfarin
• Company 515 - 3D scanning technology that measures ear canal shape and tissue compliance
• Company 516 - Bioabsorbable drug-eluting stent for chronic sinusitis patients
• Company 517 - Catheter securement system that features a small anchor placed subcutaneously
• Company 518 - Wireless systems to enable remote safety and wellness monitoring for geriatric patients
• Company 519 - An intravascular continuous glucose monitor comprising a single-use catheter and sensor system that enables direct measurement of plasma glucose in flowing blood
• Company 520 - Non-invasive meters for continuous glucose monitoring
• Company 521 - The DISTALOCK Intramedullary Nail and Drill System uses an innovative approach to facilitate the accurate placement of locking screws used to stabilize the rod-like implants, or nails, used for long bone fractures
• Company 522 - Drug-eluting balloon product for cardiac and peripheral arteries
• Company 523 - Advanced vascular closure device designed to reduce the time to hemostasis
• Company 524 - Low-energy, pain-free atrial cardioverters for atrial fibrillation (AF)
• Company 525 - Combines imaging technology and advanced algorithms to assess early embryo viability at the 4-cell stage
• Company 526 - Radiofrequency-based ablation catheter for atrial fibrillation (AF) that features integrated microwave radiometry technology
• Company 527 - Non-surgical procedure to reverse some of the physical effects of vaginal childbirth
• Company 528 - Intravenous (IV) catheter system which substantially increases successful IV insertions and provides top-of-class passive needle safety; also applicable to many other vascular access applications where higher success rates and less vessel trauma are important
• Company 529 - Spine implant system that stabilizes and restores the spinal anatomy of persons that have suffered a vertebral compression facture (VCF)
• Company 530 - 1-Trans-nasal catheter for real-time imaging of atrial fibrillation (AF) ablation procedures; 2-Intra-cardiac catheter for real-time image guidance of percutaneous valve and other structural heart repair procedures; 3-High-definition intravascular ultrasound (IVUS) system, with near-OCT image resolution; and 4-Image-guided, endoventricular injection catheter for stem cell and/or biological agent therapy for congestive heart failure (CHF)
• Company 531 - Next-generation solution for patent foramen ovale (PFO) closure that directly treats the pocket of the PFO (in-tunnel closure), while minimizing the impact to the atrial spaces
• Company 532 - Hydrogel-based ocular bandage to protect clear corneal incisions following cataract and intraocular lens placement surgery, covering vulnerable tissue as the incision heals, and reducing pain and discomfort in the days following surgery
• Company 533 - Hand-held intra-operative surgical probe used in diagnosing, staging, and treating breast cancer, to reduce residual cancer/repeat surgery after breast cancer lumpectomies
• Company 534 - Effective antimicrobial coatings and compounds that are broad-spectrum and fast-acting against clinically relevant pathogens, including multi-drug resistant strains such as MRSA
• Company 535 - Next-generation drugs with better efficacy and safety, plus longer duration of action, for rheumatoid arthritis, anemia, organ transplants, and blood diseases
• Company 536 - Next-generation extracellular matrix (ECM) products for advanced wound healing and tissue regeneration, with improved handling, strength, resorbability, and infection control over existing products
• Company 537 - Low-cost disposable devices that enable efficient and patient-friendly delivery of colonoscopy and colon prep services at convenient care settings on a walk-in basis
• Company 538 - System that provides a new direction in dialysis, through a new mode of access through two implantable ports that allow safe repeated access into arteries and veins, so that the dialysis process works with the natural direction of blood flow
• Company 539 - Polymer-based liquid bandage with antimicrobial properties to: cover intact skin or minor cuts, scrapes, burns, and minor irritations of the skin; help keep them clean and dry; and help protect them from infection
• Company 540 - Disruptive diagnostic platform, using an innovative multi-modality approach, to advance cardiovascular health assessment for the prevention of heart attack and stroke
• Company 541 - Fixation with compression technology that offers significant improvement over existing products with applications in small & long bone, spine, and the sternum
• Company 542 - First spinal instrumentation system developed specifically to restore healthy kinematics in lumbar flexion for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis
• Company 543 - A portable pneumatic compression system for the treatment of venous and arterial insufficiency, to be used in the hospital, secondary care facility, and home
• Company 544 - Revolutionary portable device to provide easy and efficient screening methods for early detection of age-related macular degeneration, diabetic maculopathy, and other types of retinal disease in the human eye
• Company 545 - Highly effective non-toxic cancer therapy based on the use of recombinant human alpha-fetoprotein conjugated with cytotoxic drug
• Company 546 - Orthopedic implants for the reconstruction of distal extremities
• Company 547 - Implant fault detection and monitoring technology
• Company 548 - Leak-proof, rupture-proof breast implant technology, with the potential to replace all existing saline and gel implants
• Company 549 - Next-generation non-invasive portable ultrasound system for the treatment of fat, skin, and other plastic surgery and dermatology applications at all anatomical sites - without anesthesia and surgery
• Company 550 - Highly multiplexed real-time PCR-based assays for the accurate detection of hospital-acquired antibiotic resistant bacteria such as MRSA, MSSA, and pathogens causing Sepsis and gastrointestinal infections
• Company 551 - 24-hour intraocular pressure monitoring of glaucoma patients by a telemetric, implantable micro sensor
• Company 552 - Electrochemical biosensors for the in-hospital diagnostics, home health care, and consumer diabetes markets
• Company 553 - New medical grade preservative that is non-toxic and capable of preserving urine, blood, plasma, and serum at room temperature; designed and used by the space program
• Company 554 - Molecular diagnostics and therapeutics for back-related and joint-related pain
• Company 555 - Technology that can detect in real time an acute myocardial infarction and derive a 12-22 lead ECG with only 3 leads or 5 electrodes
• Company 556 - Minimally invasive surgical suturing devices, using standard type curved needles and all standard sutures, for conventional and single-port laparoscopy, urogynecology, cardiac surgery, and endoscopic interventional therapies, including NOTES
• Company 557 - IVC filter utilizing unique anchoring technology that allows for optimal placement during implantation, superior migration resistance in vivo, and easy retrieval after the threat of PE has been eliminated
• Company 558 - Effective, reliable use of autologous adult stem cells (ASCs) to enhance fusion in spine and orthopedic surgery
• Company 559 - Fail-safe and inexpensive system that employs a technology to prevent errors in the intravenous administration of drugs and blood transfusion
• Company 560 - Device that applies gentle pulsing forces, in combination with standard orthodontics, to move teeth faster through accelerated bone remodeling
• Company 561 - Forward-looking intravascular ultrasound (FLIVUS) catheters that can determine correct stent size and placement through a field of view which extends beyond the catheter tip
• Company 562 - Lightweight and portable system with unsurpassed fluid balance accuracy for blood purification and fluid management
• Company 563 - Single-use, disposable "sensing embedded" surgical glove 1-to accurately map cervical length/dilatation during pre-term/full-term labor, 2-as a tool in general surgery, and 3-as a tool in telemedicine
• Company 564 - Reagents for use in non-invasive MRI, PET, and optical imaging
• Company 565 - Non-invasive device that acts as a robotic physical therapist for treating chronic head and neck pain
• Company 566 - A genomics diagnostic tool company, with a transformative technology that integrates sample preparation and sequencing on a chip, delivering actionable data in the doctor's office; supported by a $30 million large grant project with access to 15 million samples associated with cradle to grave electronic medical records established a decade ago
• Company 567 - Patient monitoring system providing real-time continuous information via four physiological parameters - sensed at the tissue level, reflecting the patient's systemic metabolic state
• Company 568 - Prevention and treatment of osteoporosis-related fractures
• Company 569 - A unique, simple-to-use, single-use inhaler device to address major unmet needs in the respiratory and drug-delivery fields; specifically, the acute treatment of asthma and COPD
• Company 570 - Growth factor, stem cell, scaffold, and bioadhesive technologies that improve the body's ability to regenerate healthy cartilage, improve joint function, and prevent degenerative disease
• Company 571 - Bioceramics for the treatment of post-myocardial infarction (MI), mitral valve regurgitation, applications to coronary and peripheral stents, and other technologies
• Company 572 - Cost-effective, laser-based antimicrobial treatments for Chronic Rhinosinusitis (CRS)
• Company 573 - Modular, 3D, real-time, stereoscopic vision and recording systems to change the surgical paradigm from 2D to 3D-HD stereoscopic vision for minimally invasive surgery (MIS)
• Company 574 - Next-generation infusion pump platform to bring new standards of accuracy and ease-of-use to the hospital and homecare markets
• Company 575 - Non-hormonal, one-size-fits-all intravaginal contraceptive ring
• Company 576 - Single-use high-definition (HD) surgical camera that will provide high-quality HD imaging at a fraction of the price of current market leading HD cameras
• Company 577 - Endoscopic accessory devices that fill unmet needs in the field of gastrointestinal (GI) endoscopy
• Company 578 - Needle technology that reveals visible blood flow at the instant of vein penetration without activation or additional instruction
• Company 579 - Non-invasive method for detecting the presence of a right-to-left cardiac shunt (i.e., PFO) to enable medical treatment and/or closure before the occurrence of a debilitating or life-threatening stroke or heart attack
• Company 580 - Patent-protected, FDA-approved, gentler power-assisted liposuction devices offering more controlled and faster fat removal, with less trauma to the doctor and patient
• Company 581 - Technology for: 1-prophylactic treatment of allergic asthma and 2-infection control in surgical theatres
• Company 582 - Non-invasive, controlled, and sustained release back-of-the-eye therapeutics for sight-threatening diseases such as: severe uveitis, diabetic macular edema, and age-related macular degeneration (AMD)
• Company 583 - Technology that can regenerate nerves
• Company 584 - Compound that can regenerate new blood vessels and has a biodegradable stent
• Company 585 - Tissue-engineered, autologous heart valves for the replacement of malformed or malfunctioning heart valves
• Company 586 - The first robotic system capable of offering full force-reflection to laparoscopic surgeons in any surgical practice
• Company 587 - An intraocular lens, customized to the patient's vision needs and adjustable throughout the patient's life, for greater quality of vision
• Company 588 - Minimally invasive stents to treat patients suffering from dysfunctional uterine bleeding (DUB), urinary tract obstruction, prostate enlargement (BPH), or prostate cancer
• Company 589 - 1-Real-time device navigation and positioning system for cardiovascular interventions and 2-Real-time angiography-based system, designed to assist in delivery of a transcatheter heart valve (THV)
• Company 590 - Biomimetic prosthetic vascular grafts that are transformed in the body into bioartificial arteries which resemble "healthy" arteries in form and function
• Company 591 - Novel neurovascular clot retrieval device for acute ischemic stroke intervention
• Company 592 - Flexible endoscopic tools for interventional gastroenterologists to perform therapeutic procedures
• Company 593 - Modern, sophisticated system to ensure a proper blood match is obtained and the patient gets the correct cord blood unit in a timely manner
• Company 594 - Implantable device to treat patients with left ventricular dilation following a Myocardial Infarction (MI) heart attack
• Company 595 - Blood glucose monitoring system designed to integrate test strips, the lancing device, and lancets into one compact glucose meter
• Company 596 - A wound dressing constructed from a biocompatible matrix and coagulating agents
• Company 597 - PediGuard is the world's first and only hand-held device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals.
• Company 598 - Hand-held, battery-powered product using intense therapeutic ultrasound (ITU) technology for skin care
• Company 599 - Bone cement for cranial defect repair
• Company 600 - A vascular robotic system designed to place coronary guidewires, stents, and balloon catheters during percutaneous coronary interventions
• Company 601 - An integrated system featuring sensors and software to enable the monitoring of seniors in multiple care settings
• Company 602 - Minimally invasive therapy for enlarged prostate
• Company 603 - Controlled Deployment Technology (CDT), which uses a low-profile access sheath that may be increased to provide a wider working diameter
• Company 604 - A portable device that provides therapeutic hypothermia in emergency care settings
• Company 605 - Hand-held, disposable nerve stimulator for use during surgeries
• Company 606 - An absorbable skin stapler for skin closure that eliminates the need for removing staples after surgery
• Company 607 - Esophageal cardiac monitoring device for use in surgery and critical care
• Company 608 - Proprietary devices for obtaining, shaping, and implanting ankle and knee cartilage grafts from foot joints
• Company 609 - Quantitative and qualitative cardiac assays to assist in the diagnosis of cardiovascular diseases at the point of care
• Company 610 - Advanced, portable and easy-to-use noninvasive devices for the assessment of traumatic brain injury (TBI) at the point of care
• Company 611 - Next-generation wellness program with sophisticated physical and mental health diagnostic software
• Company 612 - Combination of a proprietary ELISA substrate with Raman spectroscopy to dramatically increase the performance of immunoassays for diagnostics, research, and drug discovery
• Company 613 - Surgical instruments to reduce the trauma of full access surgery
• Company 614 - Non-ablative skin rejuvenation technology which produces immediate and visible aesthetic improvement together with long-term skin remodeling effects
• Company 615 - Implantable medical device that helps diabetic patients control their eating habits, lowering their blood glucose and body weight, by applying electrical stimulation to the stomach during meals
• Company 616 - Ophthalmic devices for minimally invasive treatment of corneal blindness and vision correction using proprietary corneal implants and microsurgical instrumentation
• Company 617 - Device that measures the presence, progression, and severity of any disease condition and the effectiveness of treatment and timing of non-acute death
• Company 618 - Non-obtrusive CPAP mask that uses the natural oral cavity anatomy to create the seal required for effective CPAP treatment
• Company 619 - rEEG(R) technology for the assessment of neurophysiological abnormalities and determination of psychiatric treatment
• Company 620 - Miniaturized wireless telemetry, physiological monitoring, and rehabilitation devices including applications in electrophysiology, sleep disorders, and movement disorders
• Company 621 - Dedicated Diabetic Machine (DDM) insulin regulation therapy for type 2 diabetes
• Company 622 - Non-invasive glucose monitoring device targeting the eye
• Company 623 - Universal oncology, cardiology, stroke and diabetes molecular imaging agents
• Company 624 - Implantable hearing device that provides extraordinary acoustic performance in a completely invisible device
• Company 625 - Surgical sponge detection using radiofrequency identification
• Company 626 - Home monitoring technologies with automatic fall detection capabilities
• Company 627 - Implantable neuromodulation devices for epilepsy and other neurological disorders
• Company 628 - Unique non-invasive blood pressure and cardiac output monitor, offering a precise hemodynamic profile with real-time data posted within a minute
• Company 629 - Single-port, multi-channel laparoscopic surgical platform
• Company 630 - Advanced over-the-wire vascular access device
• Company 631 - Technologies that improve visualization during laparoscopic surgery, permit laparoscopic suturing, and enable simpler removal of ureteral stones
• Company 632 - Portable hyperthermic perfusion system for raising the core temperature of the thoracic or peritoneal cavity
• Company 633 - Optical guidance systems for computed tomography (CT), fluoroscopy, and magnetic resonance imaging (MRI) procedures
• Company 634 - Liposome-encased nanoparticles for computed tomography (CT) contrast imaging
• Company 635 - Cartridge-based portable hemodialysis machine
• Company 636 - Capillary force vaporizer technology
• Company 637 - Home-based diagnosis of sleep disorders
• Company 638 - Office-based, minimally-invasive ablation device for enlarged prostate
• Company 639 - Medical imaging technologies for clinical and pre-clinical applications
• Company 640 - Ultrasound systems powered by the Scan Engine, a device that may be interchanged with any of the company's 3 carts, promoting efficiency and cost-effectiveness
• Company 641 - A drug-eluting stent coated with bioabsorbable polymers
• Company 642 - Parts and services for new and refurbished imaging and patient monitoring technologies
• Company 643 - Inhalation delivery technologies
• Company 644 - Synthetic bone substitutes
• Company 645 - Organ-specific molecular imaging
• Company 646 - Image analysis for the diagnosis of Alzheimer's and other diseases
• Company 647 - High-speed, disposable dental drill
• Company 648 - Software systems for cardiology
• Company 649 - Spinal implant for remote-controlled spine deformity and trauma correction
• Company 650 - Endoluminal treatment for morbid obesity
• Company 651 - A non-invasive diagnostic medical device that replaces the current traumatic procedure used to detect pediatric VUR (urinary reflux) and prevent kidney damage in 4M children annually
• Company 652 - Highly differentiated aorto-ostial stent and delivery platform for both peripheral and coronary applications
• Company 653 - Medical records application on a simple USB flash drive for patients, providers, and insurers
• Company 654 - Intelligent orthopedic devices that will address the growing clinical and economic cost of orthopedic implant failure and osteoporosis
• Company 655 - Pro-Vas is a novel less-invasive alternative to vasectomy for men seeking permanent contraception
• Company 656 - Minimally invasive lumbar annular repair technologies to prevent disc re-herniation and interrupt disc degeneration
• Company 657 - Innovative imaging that provides real time and wide field visualization of cancer margins during surgery to increase tissue conservation and comprehensive removal of cancerous areas, specifically for the treatment of breast cancer
• Company 658 - Device to non-invasively detect and monitor blood borne diseases in vivo, without taking blood
• Company 659 - Products ranging from needleless injection site connectors, to safety syringes, and biodiagnostic sampling devices
• Company 660 - Products for the urinary incontinence market
• Company 661 - New medical diagnostic system for the early detection of lung cancer
• Company 662 - Non-invasive ultrasound device for the treatment of glaucoma
• Company 663 - Technology that will impact the way surgeons perform laparoscopic surgery, making it possible for one surgeon to do what now requires two, and to reduce the number of surgical incisions for most all procedures
• Company 664 - Varicose vein stripping under direct vision for ablation of the diseased saphenous vein in a kit that reduces trauma, minimizes bleeding, and expects improved clinical outcomes
• Company 665 - Advanced biofeedback stimulator with diagnose and treatment modes
• Company 666 - Device for treating diseases in patients with acute renal failure (ARF) and acute inflammation induced by cardio pulmonary bypass (CPB) surgery, to produce improvement in survival rates and reduce costs
• Company 667 - Technology that bridges the gap between low-tech aspiration and complex electromechanical aspiration systems for use in thrombus removal, rotational vacuum assisted biopsy, tissue resection, and spinal disc decompression
• Company 668 - A handheld device for the as-needed treatment of allergic rhinitis
• Company 669 - Non-compressible hemostatic fibrin sealant for high-volume bleeding in intraoperative surgery and trauma
• Company 670 - Minimally invasive device for midface lift and other lift procedures
• Company 671 - Robotic ankle and foot prosthesis
• Company 672 - Handheld CD4 cell counter
• Company 673 - Auto-adjusting portable oxygen system
• Company 674 - Magnetically-guided enteral feeding tube
• Company 675 - Wireless electrocardiography
• Company 676 - Human fibrinogen-based tissue sealant
• Company 677 - Gastrointestinal endoscopy products
• Company 678 - Interventional cardiology devices for chronic total occlusions
• Company 679 - Dental imaging
• Company 680 - Type 1 Diabetes medication delivery
• Company 681 - Innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders such as migraine, Parkinson's disease, schizophrenia, and bipolar disorder
• Company 682 - In-situ formed hydrogels for radiation oncology and oncologic surgery
• Company 683 - Protein signature-based diagnostic tests for prostate, lung, and breast cancers
• Company 684 - Synthetic polymer for osteoarthritis therapy
• Company 685 - Controlled warm air delivery device for human head lice removal
• Company 686 - Polymolecular system for the treatment of inflammatory disease
• Company 687 - Critical care monitoring technologies
• Company 688 - Advanced feeding tube technology which can be placed using ultrathin endoscopes
• Company 689 - An accurate, low-cost home healthcare device for use by patients to self-measure Intraocular Pressure (IOP)
• Company 690 - Ultrasonic technologies and related techniques for aesthetic surgery
• Company 691 - Therapeutic ultrasound to treat hypertension
• Company 692 - Breast imaging system for early breast cancer detection
• Company 693 - RFID technology and software systems for medical device manufacturers, distributors, and hospitals
• Company 694 - Smart card platform that identifies and authenticates a patient to the healthcare provider and matches the patient to his or her medical record
• Company 695 - "Lap-Pak" is a flexible, one-piece, device contoured to enable the rapid and secure re-positioning of the bowels to expose the surgical site while eliminating the need for re-positioning during surgery
• Company 696 - Enhanced meter dose inhalers and spacer devices for the treatment of Asthma and COPD
• Company 697 - Sensor-based, video-monitored, automatic/semi-automatic laryngoscope that makes intubation easy, safe, and fast
• Company 698 - The first point-of-care device able to give a rapid determination of platelet quality through a multi-dimensional test, thus, avoiding the use of poor quality platelets and improving transfusion outcome
• Company 699 - Portable diagnostic device used to determine the presence and level of Myocardial Ischemia (MI)
• Company 700 - Suite of diagnostic imaging products using near-field and forced-resonance principles targeting several specialties including cardiology, oncology, orthopedics, and neurology
• Company 701 - Rapid endovascular vessel occlusion and blood flow interruption
• Company 702 - Flat panel x-ray sources for use in sterilization systems, compact CT systems, and a non-radioactive blood irradiator
• Company 703 - Non-invasive, easy-to-use device that uses pulsed radio frequency energy (PRFE) for tissue growth, wound healing, and pain relief
• Company 704 - Robotic assistance device for CT-guided soft tissue interventions
• Company 705 - Fatigue-resistant/fiber-reinforced bone cement for orthopedic joint replacement
• Company 706 - Full line of products specifically dedicated to avoiding a total joint replacement and preserving the shoulder, hip, knee, or ankle joints
• Company 707 - Single-use, disposable silver ion delivery device to treat Osteomyelitis (OM)
• Company 708 - Micro-format, CMOS-based, imaging technology for minimally-invasive, disposable endoscopic medical procedures
• Company 709 - Fish-skin-derived tissue regeneration technology for chronic wounds and hernia repair that improves upon current human and porcine technologies through improved economics & clinical performance, reduced disease transfer risk, and absence of cultural constraints on usage
• Company 710 - Hand-held ultrasound tool that displays a see-through image in the medical practitioner's line of sight, at the patient's skin surface
• Company 711 - Minimally invasive ultrasound-guided RF ablation system to treat symptomatic uterine fibroids through a transcervical approach
• Company 712 - Products for minimally invasive bypass surgery
• Company 713 - Rapid/sensitive/cost-effective diagnostic products for detecting microbes causing hospital associated infections
• Company 714 - Diagnostic products for rapid infection determination at the point-of-care (POC) for professional and consumer markets
• Company 715 - Cancer immunotherapy device, which selectively removes specific blood-borne inhibitors of the immune system
• Company 716 - POC/PST device to directly detect clot formation and do it in real time
• Company 717 - 1-Low-cost, disposable point-of-care (POC) Pap smear replacement requiring no lab or technician; 2-Disposable, woman-controlled, cervical cap embedded with an anti-HIV drug to provide contraception and help prevent infection from HIV
• Company 718 - Small/wearable/all-mechanical insulin delivery device containing a 3-day supply of insulin
• Company 719 - The next major step in the treatment of early breast cancer: replacing lumpectomy with a percutaneous, minimally invasive outpatient procedure under local anesthesia that not only eradicates the cancer, but is not disfiguring and leaves no scar
• Company 720 - Stand-alone/rapid/autologous cell harvesting processing and delivery technology
• Company 721 - System that measures airway inflammation to determine asthma severity for improved treatment
• Company 722 - Minimally invasive, image-guided therapies to treat back pain
• Company 723 - Products enhancing focally-delivered radiation and drug therapies for patients with spinal metastatic disease or bone tumors
• Company 724 - Needle-free drug delivery for migraine attacks and cluster headache episodes
• Company 725 - Image-guided ultrasound for prostate cancer tissue ablation
• Company 726 - Obstetric position tracker and ultrasound technology
• Company 727 - Compact ultrasound devices
• Company 728 - Continuous blood glucose measurement devices
• Company 729 - Radiosurgical therapy for neurovascular and inflammatory ocular conditions
• Company 730 - Wound closure technology
• Company 731 - Neurosurgical tumor removal
• Company 732 - Surgical device for treating benign prostatic hyperplasia (BPH) and other conditions
• Company 733 - Radiofrequency balloon catheter technology
• Company 734 - The TOPS(TM) System is an implantable device that allows axial rotation, lateral bending, extension, and flexion. The implant facilitates bending, straightening and twisting movements at the affected segment of the spine while blocking excessive posterior and anterior sagittal translation.
• Company 735 - Implants for sensorineural hearing loss
• Company 736 - Medical textiles for hemostasis
• Company 737 - 1-System for use in spinal surgical procedures such as vertebroplasty, 2-System to provide immediate vascular access through the intraosseous space for the delivery of essential drugs and fluids, 3-System for aspirations, biopsies, and stem cell collections
• Company 738 - Pressure cycling technology (PCT) to safely, conveniently, and reproducibly control the actions of molecules in biological samples
• Company 739 - Low-cost technology to survey the genome in its native state, in context, and at ultra-high resolution, without the need for DNA amplification
• Company 740 - Temperature management technology to treat hyperthermia and hypothermia, prevent damage from stroke, and enhance cancer therapies
• Company 741 - Unique solutions for ophthalmic conditions such as: presbyopia, myopic progression using contact lenses, intraocular lenses and lasik, or other corneal surgeries
• Company 742 - Non-invasive radiofrequency (RF) energy-based system to treat vaginal stretching caused by childbirth
• Company 743 - High-quality, cost-efficient, single-room proton beam radiotherapy (PBRT) system as an alternative to conventional high-energy x-rays
• Company 744 - Controlled, targeted deep-tissue therapeutic warming system to promote pain relief, reduce joint stiffness, and enhance recovery/rehabilitation programs
• Company 745 - 1-Artificial larynx, 2-Ear, nose, and throat (ENT) prostheses/implants
• Company 746 - microRNA-based tests to diagnose various cancers and gastrointestinal diseases
• Company 747 - Brain training software aimed at enabling individuals to strengthen cognitive function using the concept of neuroplasticity
• Company 748 - Non-invasive near-infrared (NIR) laser energy for the treatment of: acute ischemic stroke, spinal cord injury, traumatic brain injury, global cerebral ischemia, spinal cord injury, Alzheimer's disease, Parkinson's disease, and sepsis
• Company 749 - Hydrogel materials that can be fabricated into devices, nanogels, and polymer solutions with applications in ophthalmology as well as cardiology, urology, and tissue engineering
• Company 750 - Advanced polymer-based biomaterials for applications in cardiology, dentistry, orthopedics, surgery, and urology
• Company 751 - Neurostimulation device to block residual limb pain caused by complications of amputations, as well as chronic pain after surgery, and migraine pain
• Company 752 - Joint, spine, and trauma implants
• Company 753 - "Minimally invasive" gene repair
• Company 754 - Implantable device for the surgical treatment of obesity without reliance on sutures, staples, or other mechanisms that puncture the stomach wall
• Company 755 - Microdermabrasion system with polyester/nylon bristle tips and variable vacuum levels for particle-free/crystal-free performance
• Company 756 - Elastic, self-expanding devices to specifically improve left ventricle relaxation and diastolic function
• Company 757 - Point-of-care handheld immunoassay system providing high-performance quantitative laboratory blood test results in an inexpensive, portable, and easy-to-use configuration
• Company 758 - Routine serum DNA blood tests for early cancer diagnosis and management
• Company 759 - Minimally invasive alternative to the surgical treatment of obesity
• Company 760 - Drug-eluting balloons that allow for controlled release of different and even multiple substances, for the treatment of coronary (CAD) and peripheral artery disease (PAD)
• Company 761 - Cancer prognostic tests for predicting specific individual patient clinical outcomes
• Company 762 - Genomics-based in vitro diagnostic (IVD) tests developed from FFPE tissue for personalized medicine
• Company 763 - Needleless/transdermal delivery system for insulin, analgesics, or vaccines with on/off control of dosing
• Company 764 - MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the cancerous regions of the prostate gland
• Company 765 - Non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system
• Company 766 - Antimicrobial solutions to reduce the incidence of Surgical Site Infections (SSIs) in spinal surgeries
• Company 767 - Tissue repair platform that obviates the need for sutures, stapes, glues, or other foreign bodies and instead allows the body to repair and heal itself
• Company 768 - Catheter-based system to treat large vessel acute ischemic strokes
• Company 769 - Next-generation remote patient monitoring (RPM) to continuously monitor vital life-sign functions such as: heart rate, respiratory rate, body position, activity level, and skin temperature
• Company 770 - Total Artificial Heart (TAH) to replace both ventricles of a failed heart, thus, restoring the circulatory system to normalcy
• Company 771 - Antalgic-Trak(R) (A-T) is the only non-surgical spinal decompression system in the world engineered with a series of multi-axis articulating sections that provide and create spinal "Range-Of-Motion" (ROM) therapy
• Company 772 - Portable DNA analyzers for on-demand, non-batched testing, with real-time polymerase chain reaction (PCR) results in 30-60 minutes
• Company 773 - Novel biomimetic shape memory hydrogel implants for minimally invasive vessel protection following surgical treatment of degenerative conditions of the anterior spine
• Company 774 - System designed to prevent contrast-induced nephropathy (CIN)
• Company 775 - A novel suite of workflow tools that automate the viewing, analysis, and interpretation of x-rays for musculoskeletal disease
• Company 776 - Technology to preserve the normal, healthy tissue of patients that today is damaged as a by-product of current treatments
• Company 777 - Ventricular Assist Device (VAD) that can be inserted above the diaphragm
• Company 778 - Handheld, non-invasive, real-time Central Venous Pressure (CVP) monitor for cardiology and nephrology diagnostic applications
• Company 779 - Next-generation stent platform with: significantly thin walls for reduced restenosis, ease-of-use, superior deliverability, and improved radiopacity for accurate placement
• Company 780 - In-line, battery-powered, disposable, lightweight, and completely portable blood and IV fluid warming device, capable of intravenous application and irrigation warming
• Company 781 - Next-generation endovascular devices that incorporate advanced fiber optics technology into currently used products/procedures to improve patient outcomes without adding to procedure time/cost
• Company 782 - Digital fluorescence scanners for molecular pathology research, biomarker development, and clinical molecular diagnostics (MDx) for personalized medicine
• Company 783 - Software for efficiently coordinating the delivery of patient care outside of hospitals; it optimizes home care operations and can turn a medical practice into an ACO
• Company 784 - Polymer technologies for drug delivery and regenerative medicine with applications in orthopedics and spine
• Company 785 - A-FX(TM) is a minimally invasive platform technology for creating an orthopedic implant in-situ which provides superior fixation in osteoporotic bone
• Company 786 - Non-invasive device designed to offer transcutaneous pulsed electro-magnetic field stimulation therapy for treating postoperative pain and edema in superficial soft tissue
• Company 787 - Non-invasive reverse thermal gradient technology to treat conditions of tendons, ligaments, muscles, fasciae, and joints
• Company 788 - Automatic screw delivery system for cranial maxillo-facial bone fasteners
• Company 789 - Non-invasive brain physiological measurement technologies
• Company 790 - Smallest/passive/implantable tag using RFID (radio-frequency identification) technology
• Company 791 - Diabetic pain relief via topical dermal administration and controlled release of pure Nitric Oxide (NO)
• Company 792 - A percutaneous, catheter based system for the temporary isolation of the liver from the systemic blood circulation and local administration of chemotherapy drugs at high concentrations, directly into the liver without systemic side effects - under optimal drug conditions
• Company 793 - Vacuum-based clean surface nanotechnology for faster and larger osseointegration
• Company 794 - Technology for: 1-Glaucoma diagnosis and 2-Real-time homecare monitoring of intraocular pressure (IOP)
• Company 795 - Precision stapling devices enabling minimally invasive vascular connections, especially for Coronary Artery Bypass Graft (CABG) surgery
• Company 796 - The technology, based on growth factor extract from reindeer bones, improves bone formation in bone healing problems
• Company 797 - A range of injectable gels made from hyaluronic acid for applications in Aesthetic Dermatology, Ophthalmology, and Orthopaedics
• Company 798 - Mobile air purification unit that captures and destroys airborne pathogens
• Company 799 - Therapy delivery platform for the upper airway with applications to initially target chronic sinusitis, nasal allergies, cystic fibrosis, and CPAP users
• Company 800 - 1-Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures, 2-Low profile single-patient-use tissue retractor, 3-Range of 7Fr intra aortic balloon catheters with fluid-filled technology that plugs into current hardware
• Company 801 - Percutaneous anastomosis device to improve long-term vascular access for dialysis and cancer patients
• Company 802 - Intelligent 3DHD visualization and guidance platform for ophthalmic, cranial, and spine surgeries
• Company 803 - Wireless/battery-less antenna on a chip (tag) for continuous tracking of blood samples
• Company 804 - Permanently implanted electrical neural stimulators to treat balance/hearing/perceptual disorders
• Company 805 - Real-time advanced fluid sensing with smart solutions for safe preparation and delivery of IV medications
• Company 806 - Electrical stimulators via electrode garments for the treatment of pain related to chronic/acute soft tissue injuries
• Company 807 - Non-invasive neuromodulation technology platform to therapeutically address several major areas of disease; the Company's lead indication is Parkinson's Disease (PD)
• Company 808 - Surgical instrument designed to solve recurrent problems in managing sutures, tissue reattachment, and visualization during surgical procedures
• Company 809 - Nanolayer surface technology to improve the osteoconductive/bio-resistant/anti-infective attributes of implants
• Company 810 - 1-Biopsy needles with enhanced ultrasound visualization, 2-Microencapsulated tissue markers, 3-Devices for the local, accurately positioned, chemoablative treatment of soft tissue cancers
• Company 811 - The NuLens(TM) Dynacurve IOL is an implantable, flexible lens that changes it curvature in response with the movements of the eyes accommodative muscle system
• Company 812 - Systems to diagnose neurological and sleep disorders
• Company 813 - Technology that precisely eliminates irregularly shaped/invasive solid tumors while avoiding significant damage to surrounding healthy tissue and is non-toxic
• Company 814 - Extracellular matrix (ECM) implant that is completely integrated, remodeled, and replaced by the patient’s native tissue over time
• Company 815 - Non-surgical/injectable tissue revitalization and stabilization to address lower back pain (LBP) and the underlying problem of mechanical insufficiency
• Company 816 - 1-System for remote home patient monitoring of glucose, blood pressure, and thermal weight, 2-Glucose meter cell phone
• Company 817 - 1-A proprietary non-invasive ophthalmic diagnostic device designed to quickly detect elevated advanced glycosolated end products (AGEs) for very early detection of diabetes and 2-A rapid non-invasive, ophthalmic-based glucometer for painless and convenient measurement of glucose levels
• Company 818 - Implantable replacement valve to treat incompetent deep vein valves causing degenerative pain, swelling, and non-healing ulcers associated with chronic venous insufficiency (CVI)
• Company 819 - Advanced blood purification to reduce cytokine storm and inflammation that leads to multi-organ failure in sepsis and other critical care diseases
• Company 820 - Next-generation anatomic pathology (AP) with improved speed, automation, and ease-of-use
• Company 821 - Injectable biopolymer for the direct treatment of acute myocardial infarction (AMI)
• Company 822 - Endoear(R) is the world's first implantable hearing device of its kind, created for the treatment of mild to moderate hearing loss
• Company 823 - Wireless device for the treatment of stress/urge/mixed urinary incontinence (UI)
• Company 824 - Communication device that acquires neurological signals from the brain and translates them into speech
• Company 825 - Visually guided catheter ablation for atrial fibrillation
• Company 826 - Next-generation vessel closure
• Company 827 - Pneumatic compression devices targeted to the lymphedema, venous insufficiency, and sports medicine markets
• Company 828 - Technology that enables the "packaging" of chronic therapies/biologics in an easy-to-use, disposable patch-like device
• Company 829 - Instrumentation that provides surgeons with real-time sensing/feedback from the operative site
• Company 830 - Lab-free salt intake monitor for hypertension/congestive heart failure (CHF) patients
• Company 831 - Endoscopically placed device for the treatment of obesity
• Company 832 - Minimally invasive radiofrequency (RF) device to treat aging skin
• Company 833 - Optical biopsy needle that will accurately diagnose prostate cancer, yet eliminate random prostate biopsies
• Company 834 - New holding company for various orthopaedic device companies, such as Enztec and OMNI life science
• Company 835 - Catheters for dissolving/removing cerebral blood clots then delivering therapeutics to the diseased site
• Company 836 - Targeted molecular assays for onco-diagnostics/personalized medicine
• Company 837 - Biomarker discovery platform for detecting Type 2 Diabetes, Prostate Cancer, and Amyotrophic Lateral Sclerosis (ALS, aka Lou Gehrig's disease)
• Company 838 - Molecular diagnostic technologies for organ transplantation and various complex genetic disorders
• Company 839 - Non-invasive breast cancer diagnostic test via breast fluid analysis
• Company 840 - Non-invasive vascular disease detection that combines the advantages of MRI with the temporal resolution and ease-of-use of ultrasound
• Company 841 - Endoscopic/removable device that mimics the effects of gastric bypass surgery on a patient's metabolism
• Company 842 - "Smart" cells than can determine the type of disease/injury present in the body and repair/regenerate tissue accordingly
• Company 843 - Imaging systems for the non-invasive, in vivo detection of cancerous and pre-cancerous lesions
• Company 844 - Microarray-based technology enabling targeted next-generation sequencing of genomic regions of interest
• Company 845 - Minimally invasive therapy for Emphysema
• Company 846 - Comfortable, soft, and pliable cloth mask for the treatment of obstructive sleep apnea
• Company 847 - Wearable neuroimaging cap for mapping brain function
• Company 848 - Computer-controlled rehabilitation table for the management of lower back pain
• Company 849 - 1-Bioactive/conductive polymer materials and coatings for implantable biomedical devices and 2-Next-generation all-polymer leads that may be grown in the body
• Company 850 - Non-invasive tests to detect fetal chromosomal abnormalities
• Company 851 - Devices to treat low back pain
• Company 852 - Wearable sensor technology that safely and accurately measures individual sleep patterns
• Company 853 - Vascular navigation system designed to more accurately and rapidly position venous catheters (CVC and PICC)
• Company 854 - Minimally invasive breast tumor diagnosis and treatment
• Company 855 - Lightweight, waterproof, medical alert pendant for seniors - to avoid the dangers of missed medications
• Company 856 - Non-invasive DNA-based prenatal diagnostic test
• Company 857 - Heart pump technologies
• Company 858 - DNA sequencing technology for the detection of biomarkers for infectious and other diseases
• Company 859 - Computer-assisted surgical devices for total joint replacement
• Company 860 - Diagnostic and therapeutic ophthalmic devices
• Company 861 - Nanomaterials for angiogenesis/anti-angiogenesis/diagnostic applications
• Company 862 - Non-invasive neurostimulation device to restore vision to patients suffering from stroke, traumatic brain injury (TBI), dry age-related macular degeneration (AMD), and glaucoma
• Company 863 - Surgical/restorative dental implants
• Company 864 - Molecular diagnostic/prognostic tests for cancer
• Company 865 - Device to treat osteoarthritis
• Company 866 - Minimally invasive implant for treating spinal stenosis
• Company 867 - Non-polymeric drug-eluting stent (DES)
• Company 868 - Variety of diagnostic tests for infectious diseases, cardiology, hepatology, and various cancers
• Company 869 - Non-woven fabric with extended shelf-life to restore/repair tissue function
• Company 870 - Device for removing uterine fibroids without hysterectomy
• Company 871 - ALIVIOS Intelligent Eyewear enables people challenged with low vision to do more, including the ability to zoom in and out, improve brightness and contrast of whatever they are looking at, and even quickly store visual information for a closer look later
• Company 872 - Diagnostic retinal imaging system for use in the primary care setting
• Company 873 - The Unyvero(TM) System is a novel high-multiplex MDx/IVD platform for severe infectious disease (Pneumonia Application has 39 analytes: 17 pathogens, 22 antibiotic resistance markers)
• Company 874 - Inferior vena cava (IVC) filter that includes: 1-automatic self-centering, 2-bi-directional deployment and retrieval, 3 -atraumatic design, and 4-total transluminal filtration
• Company 875 - Compliant balloon platform technology for use in neuroradiology, cardiovascular, and peripheral vascular applications
• Company 876 - Mechanical thrombectomy device to treat ischemic stroke
• Company 877 - Artificial heart technologies
• Company 878 - Cancer diagnostic test which enables the development of personalized therapeutics
• Company 879 - Bone graft material that is: 1- synthetic, 2-non-immunogenic, 3-inclusive of all bone regenerative properties of an autograft, and 4-cost-effective
• Company 880 - Portable/rapid cooling technologies via the nasal cavity to improve patient outcomes after cardiac arrest, stroke, or traumatic brain injury (TBI)
• Company 881 - Tests for the diagnosis/prognosis of cardiovascular disease
• Company 882 - Cost-effective solutions for the improved detection and prevention of cancer in the gastrointestinal (GI) tract
• Company 883 - Neuromodulation for hypertension/heart failure
• Company 884 - System to repair abdominal aortic aneurysms (AAA)
• Company 885 - Endoscopic device to treat sinusitis
• Company 886 - Drug delivery platform that releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory and ischemic diseases
• Company 887 - Aortic embolic protection device for acute and long-term use
• Company 888 - Autologous adult stem cell technology, cultured from the nasal passageway, to repair damage resulting from spinal cord injury
• Company 889 - 1-Minimally invasive treatment of spinal compression, 2-Minimally invasive treatment of long bone factures, 3-Neuromodulation catheter that can be introduced into the spinal canal to treat pain
• Company 890 - Next-generation needleless drug delivery
• Company 891 - Minimally invasive neurosurgical and orthopedic instruments and implants
• Company 892 - Tissue fusion via infrared laser to replace sutures
• Company 893 - Ultrasound system that can measure true tissue elasticity in a reproducible/quantifiable/user-independent manner
• Company 894 - Next-generation nanostructured capacitors for: 1-implantable cardiac defibrillators (ICD) and 2-microsteerable cardiac ablation and related catheters
• Company 895 - Minimally invasive spine implant (facet versus pedicle screw)
• Company 896 - Spine implant that allows for post-operative adjustment of the implant size via radio control
• Company 897 - Spine fusion implant for motion preservation/dynamic stabilization
• Company 898 - Next-generation medical devices with anti-fouling surface modifications that reduce the risk of complications over long durations
• Company 899 - Device for the treatment of benign prostate hypertrophy (BPH), prostatitis, erectile dysfunction (ED), lower urinary tract symptoms, and infertility
• Company 900 - Andara technology for the treatment of acute spinal cord injury
• Company 901 - Polymer implant to repair meniscal tears via tissue regeneration
• Company 902 - Electrodes/neural interface products for functional neurosurgery and neurostimulation
• Company 903 - Non-systemic/non-invasive system that delivers magnetic versus electrical pulses for the treatment of depression
• Company 904 - Implantable neuromodulation device designed to electrically alter the pain signal pathways
• Company 905 - Next-generation implants, stem cell enabling technology, and other minimally invasive surgical instruments
• Company 906 - Invisible hearing device
• Company 907 - Cooling and compression therapy for the relief of pain/swelling after orthopedic/other surgery
• Company 908 - Catheter insertion systems, designed for extended IV dwell time, to eliminate the risk of related bloodstream infections
• Company 909 - A rapid, monthly test that uses glycated albumin to monitor gestational and type 2 diabetes more effectively
• Company 910 - Products for surgical RF ablation, valve replacement or repair, and coronary artery bypass (CABG) grafting
• Company 911 - Biomaterial with exceptional hardness/low friction/bio-inertness that also prevents the leaching of metallic ions into the body
• Company 912 - Disposable and needleless patch that can be placed on the body inconspicuously for insulin delivery - an alternative to daily insulin injections
• Company 913 - Small shunt-like device implanted into the bloodstream to modify, collect, or eliminate a broad range of Target Cells
• Company 914 - Artificial heart made of biosynthetic tissues, with two-pumps
• Company 915 - Permanently implantable/wireless/miniature sensors to transmit cardiac output, blood pressure, and heart rate data
• Company 916 - Fully implantable device for the treatment of central sleep apnea in heart failure patients
• Company 917 - Heart valve implant
• Company 918 - AdaptDx - A novel diagnostic instrument that can detect and track age-related macular degeneration (AMD) from its beginning stages, allowing for early intervention
• Company 919 - Nanotechnology-based liquid that absorbs energy on a near-molecular scale versus relying on the mechanical properties of solid materials
• Company 920 - Cyanoacrylate-based products for wound care and infection prevention
• Company 921 - Femtosecond pulse laser system for various ophthalmic applications
• Company 922 - Technology that uses the patient's own blood to make either: 1-A surgical sealant to prevent/stop bleedings or 2-A gel to stimulate the healing of chronic wounds
• Company 923 - Real-time/multi-user image communication/collaboration system that consolidates images and text records into a single point of access
• Company 924 - Polymer-based/biodegradable/drug-eluting peripheral vascular stent for tibial and infrapopliteal arteries
• Company 925 - Ultrasound-based diagnostic biosensor that enables blood analysis at the molecular level for the patient self-testing market
• Company 926 - Non-invasive biomechanical diagnostic system that records/analyzes range of motion (ROM) in a full 3-D environment for musculoskeletal diagnostics/therapeutics
• Company 927 - Full Sense(TM) Bariatric Device which is implanted and extracted via endoscopy and causes satiety leading to weight loss
• Company 928 - Continuous glucose monitoring specifically for use in the Intensive Care Unit (ICU)
• Company 929 - Real-time interactive training visualization system, specifically for the task of training any designated personnel in successfully accomplishing a limited "focused assessment with sonography for trauma" (FAST) examination
• Company 930 - Molecular diagnostic tests to: 1-Differentiate between squamous and non-squamous non-small-cell lung cancer, 2-Differentiate between mesothelioma and adenocarcinoma, 3-Identify more than 20 types of cancer
• Company 931 - Nasal stent to treat obstructive sleep apnea
• Company 932 - 1-Pacing/sensor-enabled device for Cardiac Resynchronization Therapy (CRT), 2-Real-time modality to quantify cardiac performance, 3-System that adds ingestible microchips to drugs
• Company 933 - Pocket-sized, affordable, and easy-to-use resuscitation devices that can be effectively deployed by both trained professionals and laymen
• Company 934 - Wearable health monitoring system for potential diabetes, heart disease, and sleep apnea applications
• Company 935 - Biomarkers for the screening and diagnosis of cervical and other cancers
• Company 936 - Implantable vagus nerve stimulation system for the treatment of tinnitus and post-stroke motor rehabilitation
• Company 937 - Smart, accurate guiding device based on image technology for orthopedic trauma procedures such internal fixation with intramedullary (IM) nails, osteotomy, and others
• Company 938 - Non-invasive molecular diagnostics for autism, chronic obstructive pulmonary disease (COPD), multiple sclerosis, and diseases with a genetic susceptibility
• Company 939 - Natural polymer technology that mimics the physiological clotting cascade without reliance on blood-derived proteins - to stop severe bleeding, reinforce staple and suture lines, and repair tissues
• Company 940 - Effective and convenient phototherapy system available for in-home treatment of scalp/small-area psoriasis and other photo-responsive skin diseases
• Company 941 - Electroporation-delivered/DNA-based vaccines against cancers and infectious diseases
• Company 942 - Next-generation computer-assisted laparoscopic tool composed of multiple rigid elements with intervening controllable joints
• Company 943 - Novel, POC diagnostic instrument that rapidly diagnoses blood coagulation defects based on sonorheometry - a patented ultrasound-based technology that is faster, easier to operate and interpret, and cheaper than competing technologies
• Company 944 - Fluorescent markers/optical sensors that provide an accurate and rapid determination of kidney function
• Company 945 - Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions, including diabetic diseases of the eye.
• Company 946 - The SatiSphere System is a non-invasive obesity device that safely and effectively uses the body's natural physiology to treat obesity by regulating satiation mechanisms, slowing digestion, and discouraging excessive eating
• Company 947 - Catheter ablation for the treatment of cardiac arrhythmias
• Company 948 - Monitoring products/clinical services for advanced ambulatory cardiac monitoring
• Company 949 - Technology used in: 1-Finished products designed for micro-surgical/microscopy procedures and robotics and 2-Biosensors with applications in gene expression, neuroscience, and nanotechnology
• Company 950 - Resorbable hydrogel that 1-Seals annular tears in the intervertebral disc and 2-Provides an environment for nucleus regeneration
• Company 951 - Non-invasive/fast/easy-to-use/reliable medical devices that test for neuro-visual disorders
• Company 952 - High-dose drug delivery system for the minimally invasive and repeatable treatment of liver cancers, colorectal cancer, and hepatitis
• Company 953 - Technologies that integrate bone and cartilage forming peptide and small molecule therapies with osteostimulating matrices
• Company 954 - A non-invasive, safe cardiac diagnostic system that in a 10-minute test reliably detects existence or absence of ischemia and monitors treatment efficacy
• Company 955 - Injectable porous scaffolds/spheres/composites with fully interconnected pores, for multiple applications
• Company 956 - Compact, remote, wireless, real-time device for biomedical monitoring such as cardiac, neurological, sleep disorder, obstetrics, orthopedic, and other vital signs outside the hospital/clinic
• Company 957 - Permanent implant to address mitral regurgitation directly
• Company 958 - Portable/lab-quality diagnostics for the ER/ambulance/physician's office/home/field
• Company 959 - Percutaneous injection treatment for patients with internal disc derangement (IDD) who have failed conservative care/are not yet candidates for total disc replacement (TDR)/spinal fusion
• Company 960 - Technology that allows surgeons to rapidly treat tissue at the surgical site/reduce blood loss
• Company 961 - A1c diabetes testing at the point of care, with results in under 4 minutes
• Company 962 - Next- generation/predictive blood tests to help warn of potential future health problems
• Company 963 - Vertebral compression fracture treatment
• Company 964 - Orthopedic imaging
• Company 965 - 1-Artificial vascular graft with self-sealing, non-woven, synthetic fiber structure, 2-Ventral hernia mesh
• Company 966 - 1-Prohealing coronary stent as an alternative to drug-eluting stents (DES), 2-Balloon -expandable/crush-resistant nitinol peripheral stent, 3-Nano-based transcatheter, 4-Anatomy-specific combination embolic protection and stent delivery systems, 5-Localiz
• Company 967 - Early detection of Alzheimer's disease via an eye drop and laser eye scan
• Company 968 - Drug-coated balloon angioplasty technology
• Company 969 - Behavioral remote patient monitoring system that uses wireless sensors to non-intrusively track and report on the daily patterns of seniors' activities
• Company 970 - System that assesses, then provides therapy to develop infant feeding skills
• Company 971 - Painless, continuous glucose monitoring
• Company 972 - Wireless/wearable/ultra-compact device that automatically tracks/wirelessly uploads data about a person's activities (exercise intensity levels, calories burned, sleep quality, steps, distance)
• Company 973 - Joint reconstruction device that ideally/anatomically matches the size/shape of the facet joint
• Company 974 - Platforms for: 1- Pedicle screw fixation (even with poor bone quality), 2-Vertebral compression fractures, 3-Simple- to-use trauma products
• Company 975 - Implantable device for maintaining adequate blood flow to the brain in patients experiencing a buildup of excess cerebral spinal fluid (CSF) due to trauma
• Company 976 - 1- Straightforward knotless suture anchor, 2-Instrumentation for percutaneous suture management, 3- Endotendonous repair system, 4-Shape memory staples
• Company 977 - Coagulation analyzer to eliminate unnecessary blood transfusions
• Company 978 - Simple, rapid, blood-based cancer tests to provide accurate and individualized clinical information on disease status/treatment selection/treatment response
• Company 979 - Neurostimulator for cardiac contractility
• Company 980 - Endoscopically delivered devices focused on slowing gastric emptying, to treat all stages of obesity
• Company 981 - Autonomic nervous system stimulation for pulmonary and headache disorders
• Company 982 - Optimization of T cell receptors (TCRs) for use in adoptive T cell therapy - to target and destroy cancerous/infected cells
• Company 983 - Technology for wound care and slow release drug delivery, by both transdermal and subcutaneous routes
• Company 984 - Intraoperative wavefront aberrometer for use in intraocular lens replacement surgeries
• Company 985 - Technology to treat atrial fibrillation that allows doctors to perform radiofrequency ablation under direct visualization
• Company 986 - Tests to "predict" chronic diseases/conditions, such as diabetes/osteoporotic bone fracture/a major cardiac event
• Company 987 - Disposable/miniature/minimally invasive surgical devices including reusable endoscopes for visualization, initially for use in spinal surgeries
• Company 988 - Dental implant that can be placed into a multi-rooted molar extraction site "immediately"
• Company 989 - Biocompatible and biodegradable synthetic scaffold to aid soft tissue regeneration of the anterior cruciate ligament (ACL) of the knee
• Company 990 - Ingestible/wireless capsule with sensor technology to measure pH, pressure and temperature from within the entire GI tract
• Company 991 - Counter-stimulation technology to treat Restless Legs Syndrome (RLS)
• Company 992 - Minimally invasive device to treat emphysema
• Company 993 - Gene expression test for the diagnosis of ambiguous tumors
• Company 994 - Non-invasive, rapid, quantitative measurement of metabolic health of the retina using a novel spectroscopic biomarker
• Company 995 - Implantable neuromodulation device for the treatment of chronic pain and future applications
• Company 996 - Home-use devices for hair removal/acne/skin rejuvenation
• Company 997 - Technology that restores natural physiologic outflow as a foundation of significant/steady/sustained glaucoma management
• Company 998 - Minimally invasive surgery system for simpler and safer soft-tissue suturing/fastening
• Company 999 - Effective/consistent/non-invasive neuromodulation for the treatment of urinary incontinence and future applications
• Company 1000 - 1-Needleless mesotherapy to treat cellulite, 2-Non-invasive/non-thermal treatment for skin laxity/hypertrophic scars/striae
• Company 1001 - Laparoscopic instruments that articulate/rotate/lock for single port access/"scar-less" surgery
• Company 1002 - Miniature implantable sensors to accurately/continuously pinpoint the location of tumors in real-time, during radiation therapy delivery
• Company 1003 - Manual rongeur and access tools for use in spinal decompression procedures
• Company 1004 - Convenient/improved continuous glucose monitoring system
• Company 1005 - Coating that triggers the body to generate nitric oxide (NO) at the device surface, by using naturally circulating blood substances
• Company 1006 - Real-time/in vivo/cellular-level/3-D imaging for: image-guided surgery; early cancer diagnosis without a biopsy
• Company 1007 - In vivo transdifferentiation to regenerate ischemic/diseased organs
• Company 1008 - Technology that has demonstrated its usefulness in tracking all facets of in vivo oxygen metabolism using normally installed MRI scanners
• Company 1009 - True seizure "prediction" - up to an hour before the event
• Company 1010 - Wearable mobile device to accurately measure real-time energy (calorie) expenditure/combat obesity
• Company 1011 - 1-Non-embryonic cell technology that creates cells/tissues/organs for virtually anyone needing a transplant, 2-Non-toxic cancer vaccine that uses the body's natural immune response to fight cancer, 3-Cell separation system to diagnose/monitor cancer
• Company 1012 - Custom miniaturized mechanical components/devices for a broad range of medical device applications
• Company 1013 - Wireless/disposable sleep-monitoring device
• Company 1014 - 1-Next-generation, natural fibrin sealant, 2-Human thrombin
• Company 1015 - In vivo smart sensor to help women get pregnant, automatically detecting pregnancy and any early pregnancy loss, and screening for cervical cancer and other STDs, with additional uses central to women's health & lifestyle
• Company 1016 - Technologies that focus on wound diagnostics, infection control, and wound therapy
• Company 1017 - Wireless/MEMS-fabricated/nano-processed/dermal/percutaneous continuous glucose monitoring device
• Company 1018 - Diagnostic instrument to measure the material properties of bone
• Company 1019 - Electronic Brachytherapy (eBx) systems based upon miniaturized x-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments
• Company 1020 - Minimally invasive method for lumbar spine decompression to treat patients with lumbar spinal stenosis (LSS), which may be performed in conventional operating rooms or interventional radiology suites with fluoroscopic imaging
• Company 1021 - Next-generation respiratory device that delivers synchronization of flow/temperature/humidity/oxygen percentage, without discomfort, via nasal cannula
• Company 1022 - Minimally invasive system to treat emphysema and resolve prolonged air leaks following lung surgery
• Company 1023 - 3-D mesh pouches that are implanted empty, positioned, filled, then deployed to their full size for spinal/orthopedic applications
• Company 1024 - Painless photo-pulsation technology for diminishing fine lines/wrinkles/age spots on the face/neck/hands
• Company 1025 - Plastic surgery implantable devices for cosmetic and reconstructive surgery
• Company 1026 - The SENSIMED Triggerfish(R) "eye-Holter" is a paradigm-changing technology consisting of a disposable contact lens telemetric sensor, which for the first time provides ophthalmologists with the full ambulatory 24-hour IOP profile, conveniently and during uninterrupted daily activities and sleep
• Company 1027 - Technology for the non-fusion treatment of scoliosis
• Company 1028 - Atraumatic injectable plugs for 1-Temporary occlusion of blood vessels, 2-Kidney stone removal, and 3-future applications
• Company 1029 - Percutaneously deliverable endograft to treat Abdominal Aortic Aneurysms (AAA) and Thoracic Aortic Aneurysms (TAA)
• Company 1030 - Optical Coherence Tomography (OCT) for sub-surface biological tissue imaging at much greater resolution than ultrasound/MRI/CT scanners
• Company 1031 - Next-generation femtosecond laser that can operate inside the eye to make cataract surgery safer/more effective
• Company 1032 - Totally implantable pumps delivering targeted medications directly to the spinal cord
• Company 1033 - Point-of-care diagnostic tests for infectious diseases capable of detecting virulence markers produced only during ACTIVE infections
• Company 1034 - Therapeutic gene delivery
• Company 1035 - 1-Vertebral augmentation system and 2-On-demand ultra-high viscosity cement injection, for spinal applications
• Company 1036 - Miniature implantable neurostimulator for treating central nervous system disorders
• Company 1037 - Simple, point-of-care blood test for the detection/monitoring of traumatic brain injury (TBI)
• Company 1038 - Resurfacing system to treat lesions/defects in the body's weight bearing, non-weight bearing, and extremity joints
• Company 1039 - Molecular imaging of apoptosis (programmed cell death) for disease detection/monitoring
• Company 1040 - Technology to close incisions made during Natural Orifice Transluminal Endoscopic Surgery (NOTES) procedures
• Company 1041 - Transitional in vivo imaging
• Company 1042 - Collapsible titanium-alloy implant for spinal fusion
• Company 1043 - Non-invasive type 2 diabetes and pre-diabetes screening with no blood draw/no fasting/no waiting for a lab result
• Company 1044 - Devices for the destruction of pathogens responsible for: heart/blood/respiratory/gastrointestinal/periodontal/otological diseases, pancreatic cancer, and toe nail fungus
• Company 1045 - Device that delivers a low-level/precisely controlled heat for the treatment of acne
• Company 1046 - Nanomaterial-based MRI coil for higher image quality/faster scan times
• Company 1047 - Handheld/at-home hair removal via laser
• Company 1048 - Enhanced diabetes insulin pump
• Company 1049 - Transpedicular/minimally invasive approach to vertebral body reconstruction/anterior spinal column support
• Company 1050 - Next-generation Spinal Cord Stimulation (SCS) technology to treat chronic back/lower extremity pain
• Company 1051 - Dynamic and intelligent optics for use in spectacle lenses for the correction of presbyopia
• Company 1052 - Blood screening tests for breast and ovarian cancers
• Company 1053 - Implantable/battery-less diagnostic system to allow orthopedic surgeons to monitor spinal fusion progress
• Company 1054 - Next-generation coatings/advanced drug-delivery systems for cardiovascular stents and other implantable medical devices
• Company 1055 - Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) device for acute coronary syndrome (ACS) and heart failure patients
• Company 1056 - Ultra-thin/personalized/single-use/flexible/transdermal drug delivery patch
• Company 1057 - DNA-based diagnostic tests for early identification/management of cancer/acute diseases
• Company 1058 - Device with bio-active formulae to rapidly/painlessly treat/control the wound environment
• Company 1059 - Less invasive treatment for chronic sinusitis delivered via non-nasal access
• Company 1060 - Leadless/implantable pacing device for left ventricular stimulation/the treatment of heart failure
• Company 1061 - Technologies to acquire/process/visualize data from 3-D breast imaging
• Company 1062 - Mental stimulation system to help maintain mental acuity/quality of life
• Company 1063 - Implantable device to treat high blood pressure that cannot be controlled with medications/lifestyle modifications
• Company 1064 - Polymer technologies for cardiac/cranio-maxillofacial/orthopedic surgery applications
• Company 1065 - Leadless/subcutaneously implantable cardiac defibrillator (ICD)
• Company 1066 - 1-Handheld intelligent bone sculpting tool, 2-X-ray vision that appears "within" the patient
• Company 1067 - Synthetic peptides for tissue regeneration for the treatment of musculoskeletal/vascular/chronic wound diseases
• Company 1068 - Radiofrequency (RF) energy to reshape the cornea without incision
• Company 1069 - Endovascular treatment of peripheral arterial blood vessels that require re-vascularization
• Company 1070 - Cells derived from bone marrow which can be used in an allogeneic/off-the-shelf setting to treat kidney/other difficult to treat diseases
• Company 1071 - Thin-walled/removable/entirely covered stents designed to match the site to be treated and the surrounding anatomy
• Company 1072 - Technologies to: 1-Treat the progression of age-related macular degeneration (AMD) and retinitis pigmentosa (RP), 2-Stop/reverse some of the vision loss from Glaucoma, 3-Prevent diabetic retinopathy, 4-Greatly enhance pars plana vitrectomy surgery
• Company 1073 - Single device for high-frequency ultrasound imaging/therapeutic treatment
• Company 1074 - Low-level laser technology for aesthetics, bone healing, neck/shoulder pain, and wound healing
• Company 1075 - Light-based aesthetic systems that are pain-free/seven times faster than existing systems
• Company 1076 - 1-Image analysis technology for virus detection/analysis, 2-Antiviral drugs
• Company 1077 - Simultaneous testing of sobriety and identy that is simple/rapid/non-invasive, requiring no bodily fluids
• Company 1078 - Technology for diagnosing breast and ovarian cancers and determining responsiveness to new therapeutics
• Company 1079 - Synthetic graft/stent technology that reduces neo-intimal hyperplasia (NIH) and occurrence/rate of restenosis
• Company 1080 - Disposable endoscopic assist device that can be used with existing equipment to significantly improve flexible endoscopy procedures
• Company 1081 - Systems using radiofrequency (RF) energy for the treatment of GERD and fecal incontinence (FI)
• Company 1082 - Sutureless anastomosis systems to reduce/eliminate cross clamping time and suturing during minimally invasive surgery (MIS)
• Company 1083 - Anti-infective compounds designed to mimic host defense proteins, but with completely synthetic/non-peptide backbones, for serious, life-threatening, acute disorders
• Company 1084 - Minimally invasive interstitial laser therapy (ILT) as an alternative to lumpectomy
• Company 1085 - Less invasive approach for mitral valve repair, on a beating heart
• Company 1086 - High-resolution dermoscopy imaging technology to identify melanoma at an earlier stage/reduce the number of unnecessary excisions
• Company 1087 - Nanotechnology surface treatments for combination medical devices that address nosocomial (in-hospital) infections and thrombus
• Company 1088 - Non-invasive, fully automated system for the accurate assessment of: cardiovascular/diabetic autonomic neuropathy, effectiveness of beta-blocker therapy, and risk stratification of sudden cardiac death
• Company 1089 - Wireless/motorized orthopedic lengthening implants for applications in deformity correction/cosmetic limb lengthening/bone fractures
• Company 1090 - 3-D scaffold that enhances the biointegration of percutaneous/fully implanted current and next-generation devices
• Company 1091 - Injectable gels for localized and controlled release of biologicals
• Company 1092 - Portable/palm-held endoscopic imaging with a mobile platform for recording/sharing/archiving images
• Company 1093 - Hand-held ultrasound device to quantify strain and stiffness of tendons/ligaments
• Company 1094 - Lightweight brace support suit that restores mobility function for paraplegics/lower limb paralysis patients
• Company 1095 - Non-invasive gene expression-based tests for the monitoring of transplant rejection/autoimmune diseases
• Company 1096 - Cobalt-chromium, balloon-expandable stent, which marries with approved DES to treat the entire spectrum of coronary artery bifurcation lesions
• Company 1097 - Non-invasive intracranial pressure monitor to diagnose/treat head injury
• Company 1098 - Temperature-controlled/multi-functional next-generation cutting/sealing product
• Company 1099 - Interspinous/interlaminar functionally dynamic stabilization device and other non-fusion scoliosis technologies
• Company 1100 - CO2 lasers through flexible/rigid endoscopes for use in minimally invasive surgery and soft tissue procedures in otolaryngology/head and neck surgery/pulmonology
• Company 1101 - Real-time/PCR-based molecular diagnostic tests for life-threatening respiratory fungal infections
• Company 1102 - Ultra-lightweight/soft/non-palpable mesh technology to treat urinary stress incontinence/pelvic organ prolapse
• Company 1103 - Medipacs first-ever, solid-state polymer pump platform is the "end-game" for low cost, high precision drug delivery solutions and it will spawn electronic syringe products that reformulate markets
• Company 1104 - Surgical implants and biological products for spinal surgery
• Company 1105 - In situ formed hydrogels designed/indicated for ophthalmic surgery
• Company 1106 - Light-activated glue system to stabilize shattered bone
• Company 1107 - Non-contact imaging system that provides local anatomical and oxygenation information
• Company 1108 - Affordable/good quality standard-of-care surgical devices
• Company 1109 - Low-dose-rate brachytherapy that will replace individual seeds and provide more uniform/consistent radiation delivery to patients
• Company 1110 - Recombinant adeno-associated viral (AAV)-based gene therapy as a treatment for congestive heart failure (CHF)
• Company 1111 - Aortic valve bypass graft system for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy
• Company 1112 - Single-use catheter device w/controller that delivers radiofrequency energy during outpatient bronchial thermoplasty for the treatment of asthma
• Company 1113 - Ultrasonic energy for the selective dissection/fragmentation/debridement/cleansing of tissues
• Company 1114 - Percutaneous soft tissue lifts for the breast/neck/other soft tissue structures
• Company 1115 - Bioresorbable polymer surgical implants designed to prevent/reduce the formation of post-operative adhesions
• Company 1116 - Implanted electronic subretinal device to restore vision to those who are blind due to retinitis pigmentosa (RP) or age-related macular degeneration (AMD)
• Company 1117 - Noninvasive tests for the risk assessment of cardiovascular disease and the detection of early-stage lung/breast/colorectal cancer
• Company 1118 - Guidewire system intended to safely/quickly cross occluded peripheral and coronary vessels
• Company 1119 - Matrix therapy based technology that treats skin ulcers/reduces amputation
• Company 1120 - Artificial muscle technology for the treatment of sphincter dysfunction and urinary incontinence (UI)
• Company 1121 - Technology that selectively treats only cancer cells and avoids destruction of normal cells
• Company 1122 - Full line of precision-crafted/disposable/ultra-minimally invasive surgical instruments
• Company 1123 - Beam steering/target tracking/treatment planning solutions to the external beam radiation therapy market
• Company 1124 - Device that uses combined electric field and low-intensity, noninvasive ultrasound for the treatment of solid tumors without the need for chemotherapy
• Company 1125 - One-shot, instantaneous anastomotic stapling devices for open AAA, EVAR, and CLI applications
• Company 1126 - Stent to treat cerebral/aortic aneurysms by modulating hemodynamic flow
• Company 1127 - Biomotion sensors that enable easy/non-contact capture of high-quality physiological data - remotely/wirelessly
• Company 1128 - Flexible/single-use/sterile video-endoscopes which may be used at the patient bedside and which avoid all cross-contamination risks
• Company 1129 - Therapeutic gene delivery to treat diabetes/obesity/intestinal disorders/hemophilia/anemia
• Company 1130 - Non-invasive technique for sampling the surface layers of the skin to generate individual genetic profiles for diagnostic/prognostics
• Company 1131 - Non-invasive method designed to only kill fat cells and not harm the skin or other tissue
• Company 1132 - 3-D/single-piece/dual optic accommodating intraocular lens (IOL)
• Company 1133 - Cellular therapy to act directly at the level of the cause of autoimmune disorders, the dysregulated immune regulation
• Company 1134 - Next-generation transluminally placed endovascular grafts for the treatment of aneurysmal disease in the AAA/TAA
• Company 1135 - The first tomographic, real-time, high-resolution imaging system for pulmonary disease management. The Tomophase OCTIS(TM) is being deployed in major hospitals worldwide.
• Company 1136 - Very strong/customizable/biomimetic/easily revisable artificial disc implant, requiring no assembly in situ
• Company 1137 - Diagnostic and therapeutic catheter-based devices for prevention/treatment of heart attacks caused by soft plaque
• Company 1138 - Advanced method of photocoagulation to provide more rapid, precise, and safe treatment for a variety of retinal conditions
• Company 1139 - Next-generation personal diagnostics for hematological malignancies/autoimmune disorders
• Company 1140 - Soft tissue repair/replacement, using proprietary chemistry and organic collagen matrices
• Company 1141 - Sirolimus-based product as a next-generation therapeutic for the treatment/prevention of wet AMD and the treatment of diabetic macular edema
• Company 1142 - Phototherapy/ultraviolet light to inactivate the organisms that cause nail infections
• Company 1143 - Technology enabling detection and monitoring wirelessly, remotely, and with no contact to the subjects; also through clothing/barriers
• Company 1144 - Biochips to identify gene expression patterns
• Company 1145 - Automated blood analysis at point-of-care
• Company 1146 - Applicator for breast brachytherapy that delivers targeted dose of radiation
• Company 1147 - MRI contrast agents to monitor the position/quantity of transplanted cells non-invasively in vivo
• Company 1148 - A soft tissue aperture fixation system for anterior cruciate ligament (ACL) reconstruction using the hamstring/other soft tissue grafts
• Company 1149 - Non-invasive/convenient measurement and monitoring of human hydration status, using saliva as a sample
• Company 1150 - Cryotherapy to ablate diseased tissue
• Company 1151 - Reliable/accurate/solid-state laser system for customized treatment of many vision disorders
• Company 1152 - Non-invasive/iontophoretic drug delivery system with broad applicability for treating serious ocular diseases
• Company 1153 - Electrical stimulation technology, along with single-use disposables, to restore continence control to individuals with abdominal ostomies and eliminate the need for traditional ostomy pouching systems
• Company 1154 - MRI-guided laser ablation system for targeted, minimally invasive, focal tumor therapy
• Company 1155 - Medical devices that enable earlier detection/minimally invasive treatment of lung cancer
• Company 1156 - Non-invasive devices for the treatment of superficial venous disease
• Company 1157 - High-quality low-cost spine implants
• Company 1158 - 1-Catheter-based system for the treatment of ischemic brain injury; 2-Drug delivery systems; 3-Microcatheters; and 4-Aneurysm coil delivery systems
• Company 1159 - Cardiac assist device for patients in moderate/severe long-term heart failure
• Company 1160 - Digital image acquisition, coupled with proprietary CAD decision-making algorithms, to provide an immediate/automated colposcopic evaluation
• Company 1161 - Robotic system for fabrication of nano-material based wound dressings, delivered on-demand, at the POC
• Company 1162 - Unique spine functional testing that delivers improved surgical outcomes
• Company 1163 - Electromagnetic thermal therapy to relieve pain/improve function in patients suffering from osteoarthritis
• Company 1164 - System to inactivate pathogens in all three major blood components: platelets/plasma/red cells
• Company 1165 - Therapeutic approaches to prevent the abnormal tissue growth that inhibits recovery from surgical procedures/impairs normal wound healing
• Company 1166 - Biocompatible shape memory polymers which can be programmed to change shapes/rigidity when an initiating stimulus is applied
• Company 1167 - A fully integrated, affordable, sample-to-result platform for rapid, accurate PCR-based detection/differentiation of infectious disease
• Company 1168 - Technologies that will prevent infection for many large patient populations
• Company 1169 - Light-activated drug therapy to transform cancer into a treatable chronic disease
• Company 1170 - 1-Percutaneous venous valve, 2-Inferior vena cava filter, 3-Multi-purpose/disposable laparoscopic scissor grasper, 4-Multi-sized/multi-stiffness guidewire
• Company 1171 - Non-invasive infrared imaging system for the early detection of breast cancer
• Company 1172 - Device for the treatment of sudden cardiac arrest for both in- and out-of-hospital markets
• Company 1173 - Line of antimicrobial coatings to prevent microbial colonization/biofilm formation of endotracheal tubes/other indwelling medical devices
• Company 1174 - 3-D tracking devices for use in surgical navigation and MIS
• Company 1175 - Implantable patient alerting system for the detection and prevention of heart attacks
• Company 1176 - Minimally invasive/RF nerve ablation to reduce of migraine headache pain
• Company 1177 - Less invasive devices for the treatment of glaucoma, intended to replace current therapies
• Company 1178 - Natural cell-based technologies to restore normal neuron function in the central nervous system
• Company 1179 - Non-invasive/urine-based diagnostic assays for specific cancer types
• Company 1180 - Fluid-controlled accommodating intraocular lens (IOL) to restore vision of youth to middle-aged/elderly individuals
• Company 1181 - Single, multi-cannula laparoscopic port and specially designed curved instrumentation
• Company 1182 - Technology that provides the precision of a scalpel and the bleeding control of traditional electrosurgery, without extensive collateral tissue damage
• Company 1183 - More viable/cost-effective method for treating intracranial aneurysms
• Company 1184 - System that enables consistent tissue contact/complete lesions during cardiac surgery for the treatment of arrhythmias
• Company 1185 - Non-invasive neurorehabilitation system
• Company 1186 - Cerebral protection system to prevent embolic strokes
• Company 1187 - Catheter-based drug delivery using high-frequency/low-power ultrasound
• Company 1188 - Technology for real-time identification/localization of cancer cell clusters to enable complete/residual-free therapeutic excisions
• Company 1189 - Third-generation cancer-associated biomarkers using proteomics
• Company 1190 - Cardiac mapping system that is non-invasive, maps the entire heart in one beat, and provides catheter localization
• Company 1191 - Repair and regeneration technology platforms designed to mend and regrow hard tissue (such as bone) and soft tissue (such as cartilage)
• Company 1192 - Minimally invasive/flexible spinal implant technology to treat vertebral compression fractures and degenerative disc disease
• Company 1193 - Catheter-based drug delivery system designed to dissolve blood clots in a single/rapid/one-step procedure
• Company 1194 - Rapid DNA-based point-of-care diagnostics
• Company 1195 - Joint prostheses as an adjunct to laminectomy/laminotomy/neural decompression/facetectomy, in lieu of fusion
• Company 1196 - Advanced trilobal pericardial valve technologies
• Company 1197 - Protective coatings for medical instrumentation to combat bacterial biofilms
• Company 1198 - Wireless ECG monitoring
• Company 1199 - De-cellularized biological scaffolds meant to function like native tissue
• Company 1200 - Non-invasive, wearable, watch-sized metabolism measurement system that employs the use of a low-cost proprietary disposable sensor using direct-calorimetry, to accurately measure minute-by-minute caloric expenditures
• Company 1201 - Advanced, intuitive real-time imaging for abdominal minimally invasive surgery
• Company 1202 - Technology that improves vascular access accuracy and visualization of veins and arteries as well as related vascular events such as rolled veins, bifurcations, vasospasm, and extravasation
• Company 1203 - Regenerative medicine company developing novel treatments from hair growth to cancer therapies based on the products of cells grown under simulated embryonic conditions
• Company 1204 - Next-generation cell-based/tissue-engineered products
• Company 1205 - Mesh wrap for permanent implantation around the heart to prevent/reverse the progression of heart failure
• Company 1206 - Handheld/breath-based blood glucose monitor
• Company 1207 - More targeted/accurate radiation of cancer cells with significantly fewer side-effects
• Company 1208 - Bioactive glass-ceramic material that offers whiter and less-sensitive teeth while protecting from tooth decay
• Company 1209 - Membrane optimization, coatings technologies, and development of polymers for biomedical applications
• Company 1210 - System to process/concentrate cellular components from autologous bone marrow, including adult stem cells, at the point-of-care and in just 15 minutes
• Company 1211 - Devices to control bleeding post-hysterectomy/in other cases of pelvic area trauma
• Company 1212 - Safe, non-invasive body shaping technologies
• Company 1213 - Non-invasive/fast/accurate diagnostic kits for: fertility, hormones, infectious agents, auto-antibodies, and tumor markers
• Company 1214 - Gene therapy products for the treatment of inherited/acquired diseases.
• Company 1215 - Stent technology for the treatment of atherosclerotic disease at/near bifurcations
• Company 1216 - Neo-organs/tissues derived from the patient's own (autologous) cells
• Company 1217 - Computer-controlled pressure garments for the effective treatment of lymphedema/chronic wound healing
• Company 1218 - Small/portable/disposable infusion pump kit to treat post-operative pain more effectively than narcotics
• Company 1219 - Pulsatile perfusion generator technology to greatly enhance the preservation time window and organ transplant quality
• Company 1220 - The Argus II Retinal Prosthesis System is the world's first and only CE marked retinal prosthesis that utilizes electrical stimulation to partially restore sight in patients blinded by outer retinal degeneration
• Company 1221 - Device to improve drainage following heart, lung, and trauma surgery, as well as other procedures where drainage is critical
• Company 1222 - Next-generation/fully-automated/electronically-controlled/self-contained blood glucose system
• Company 1223 - Minimally invasive system for treating long-bone fractures using an intermedullary stent/cement
• Company 1224 - Non-invasive measurement of magnetic fields to diagnose functional brain disorders
• Company 1225 - Products to diagnose/treat dry and wet age-related macular degeneration (AMD) and other chronic diseases involving the alternative complement system
• Company 1226 - Wearable artificial kidney device
• Company 1227 - Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1228 - Miniature patch that dispenses insulin
• Company 1229 - Microcatheter and imaging technologies for interventional ophthalmology
• Company 1230 - Easy, safe, and convenient injection of drugs and vaccines in a solid dosage form using the Glide SDI(R) (Solid Dose Injector)
• Company 1231 - Non-epigenetic cell reprogramming technology that enables the generation of patient-identical replacement tissue/organs on an as-needed basis
• Company 1232 - Device to percutaneously repair the mitral valve
• Company 1233 - Miniature intravascular flow augmentation device for every organ that needs temporary change of flow
• Company 1234 - Minimally invasive surgical procedure intended to reduce the incidence of stroke/thromboembolism associated with atrial fibrillation
• Company 1235 - Plaque vulnerability biomarkers to detect patients at risk for the development of stroke, myocardial infarction or claudication
• Company 1236 - A platform for minimally-invasive cardiac surgery (MICS) via single-port, subxiphoid access, and an endoscope that reaches any anatomical location, including complex paths, from one single access port
• Company 1237 - Percutaneous mitral valve replacement (PMVR) for Mitral Regurgitation (MR)
• Company 1238 - Medical devices for the osteoarthritis/rhinosinusitis markets
• Company 1239 - Miniaturized ultrasound probe that is easier-to-use/more flexible
• Company 1240 - Resonating sensor made out of piezoelectric ceramics that can be miniaturized and is suitable for use in diagnostic equipment
• Company 1241 - Bioresorbable peripheral/coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty
• Company 1242 - Disposable devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1243 - True 3-D imaging to improve evaluation/planning of radiation treatments
• Company 1244 - Next-generation spinal implants
• Company 1245 - New unilateral posterior fusion technology
• Company 1246 - Products for nuclear replacement/augmentation, vertebral compression fracture repair, and spinal fusion
• Company 1247 - Second-generation, metal-on-metal cervical/lumbar artificial discs
• Company 1248 - Artificial cervical disc with controlled range of motion in all six degrees of freedom
• Company 1249 - Next-generation of biomaterials for spinal implants
• Company 1250 - Intradiscal arthroplasty device utilizing articulating PEEK-on-PEEK material
• Company 1251 - Hydrogel matrix with applications across multiple specialties
• Company 1252 - Intelligent microgels as injectable scaffolds for intervertebral disc repair
• Company 1253 - Minimally invasive disc augmentation system to repair/rehabilitate an intervertebral disc
• Company 1254 - Implant designed to retain motion following the removal of diseased disc and/or bone material in the upper spine
• Company 1255 - Tissue repair/surgical mesh systems for soft tissue repair
• Company 1256 - Silicon nitride implants with 3-D structured cancellous ceramic for strong capillary action
• Company 1257 - Tibial knee implant for stable fixation to the medial tibial plateau without bone cuts/cement/screws
• Company 1258 - Technologies to treat obstructive sleep apnea and snoring
• Company 1259 - The Superion Interspinous Spacer system is the most advanced and least invasive spacer system and is delivered through a percutaneous midline approach for the treatment of lumbar spinal stenosis
• Company 1260 - Tissue engineering technologies for orthopedic/sports medicine patients
• Company 1261 - Real-time imaging/image guidance for the operating room
• Company 1262 - Stent that provides protection from embolic showers during/post-procedure
• Company 1263 - Minimally invasive vapor technology to treat emphysema
• Company 1264 - Human-based tissue scaffolds
• Company 1265 - Simple, low-cost infusion pump that contains the IV bag within it
• Company 1266 - Non-intrusive patient-monitoring systems that facilitate timely intervention for cardiac/respiratory deterioration
• Company 1267 - Bifurcated stenting
• Company 1268 - Bioabsorbable implants for accurate soft tissue fixation either to apposing soft tissue/to bone
• Company 1269 - Drug delivery vehicles that can easily be targeted to specific cell types/disease state tissues
• Company 1270 - Minimally invasive therapies for interventional neuroradiology
• Company 1271 - Treatment for ischemia via stem cell-based therapies
• Company 1272 - Cellular therapy device to treat liver disease
• Company 1273 - Customizable vibration therapy devices to stimulate bone/muscle tissue
• Company 1274 - Deep brain stimulation (DBS) guidance system
• Company 1275 - Cellular imaging technology, using the Internet to transfer real-time/secure/accurate cellular resolution images
• Company 1276 - Minimally-invasive percutaneous aortic valve replacement systems
• Company 1277 - Off-the-shelf implantable allograft tissue to support peripheral nerve repair and regeneration
• Company 1278 - Advanced detection, staging, endoscopic treatment and follow-up care for acute and chronic lung disease
• Company 1279 - Minimally invasive therapy for the treatment of chronic disc pain
• Company 1280 - A minimally invasive device for stomach-reduction surgery consisting of a stapling tool that can be passed down the throat into the stomach
• Company 1281 - Kidney stone management device and urethral dilating introducer
• Company 1282 - Ventricular elastic support therapy for heart failure
• Company 1283 - Plastic medical devices for gynecological exams and surgeries
• Company 1284 - Inferior vena cava filters
• Company 1285 - Neuromodulation system for both traumatic brain injury (TBI) and stroke
• Company 1286 - Minimally traumatic, bone- and cartilage-preserving knee implants and instrumentation
• Company 1287 - Radio-frequency (RF)-based tissue sealing and cutting instruments with a long jaw sealing length and high quality seal to greatly reduce procedure time and surgeon fatigue
• Company 1288 - Fast, accurate, and easy-to-use in vitro molecular diagnostic products that rapidly identify infectious pathogens
• Company 1289 - Unique spinal implant designed to promote rapid fusion
• Company 1290 - Devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1291 - Unique transcranial magnetic stimulation system that allows direct non-invasive activation of deep brain structures
• Company 1292 - Dynamic "shape memory" platform to optimize mitral/tricuspid valve repair
• Company 1293 - Single molecule DNA analysis system, with no requirement for prior sequence information/PCR/cloning/probes
• Company 1294 - Biomaterials-based medical devices focusing on cardiovascular, metabolic, inflammatory, and fibrotic diseases
• Company 1295 - Transdermal/wound dressing/mucosal drug delivery
• Company 1296 - A unique solution similar to ring annuloplasty/edge-to-edge repair, all in one modality, for mitral valve repair
• Company 1297 - Minimally invasive devices that improve oxygenation for patients with COPD
• Company 1298 - Hands-free internal retractor/internally-anchored laparoscope camera cleaner
• Company 1299 - Particle technologies for the treatment/prevention of chronic respiratory disorders
• Company 1300 - Minimally invasive, single-procedure approach for the repair of cartilage damage/osteoarthritis
• Company 1301 - Biodegradable synthetic hydrogels for general and specialty surgery use
• Company 1302 - Silk-based biomaterial platforms for tissue rejuvenation/connective tissue repair
• Company 1303 - Ankle replacement implant for patients with chronic pain/arthritis
• Company 1304 - Biomarker assays for the early detection of cancer
• Company 1305 - 1-Painless intradermal drug delivery, 2-GERD diagnostic device, 3-Non-invasive continuous glucose monitoring
• Company 1306 - Detection products for viral/bacterial infections, genetic diseases, mutations, cancers, etc.
• Company 1307 - Video integration and equipment management system to enhance the MIS market
• Company 1308 - Multi-pixel x-ray source for enhanced system performance/new capabilities
• Company 1309 - Combination ultrasound/electrical stimulation device for skin rejuvenation
• Company 1310 - Bioprosthetic two-piece tissue valve system for minimally invasive valve replacement utilizing a transapical approach
• Company 1311 - Advanced suturing technology for minimally invasive/NOTES/bariatric/cardiac/other surgical specialties
• Company 1312 - A minimally invasive electromagnetic navigation system for early detection of lung cancer
• Company 1313 - Patient-centric data system and analysis tools for translational medicine and research
• Company 1314 - Hand-held device to monitor post-operative/trauma patients for early warning signs of sepsis or infection in the bloodstream
• Company 1315 - Spinal cage with dynamic stabilization/MIS placement (3mm access) and easily revisable
• Company 1316 - Fully modular total hip replacement systems to reduce wear/add longevity
• Company 1317 - A "plug & play" system for treating non-invasive, curative, and palliative cancers and precursors
• Company 1318 - Products for the early detection of lung and oral cancers
• Company 1319 - System that performs a non-invasive, 30-second test to identify the risk of heart disease
• Company 1320 - Non-molecular bacterial screening, identification, and antibiotic susceptibility testing
• Company 1321 - Optical coherence tomography for evaluation of human tissue microstructure with real-time depth visualization
• Company 1322 - Wireless electronic skin patch sensors for the real-time measurement/monitoring/diagnosis/clinical management of cardiac arrhythmias
• Company 1323 - Non-fusion spinal solutions that control segmental motion/maintain the neutral zone simultaneously
• Company 1324 - Optical cell sorters used in stem cell/cell therapy treatments for cancer, autoimmune disease, and regenerative medicine applications
• Company 1325 - BQT®, a non-invasive point-of-care diagnostic test for osteoporosis and bone fracture risk
• Company 1326 - Low-mass PFO closure system capable of repairing the defect from within the tunnel
• Company 1327 - Third-generation biodegradable annuloplasty rings
• Company 1328 - Easy-to-use, instrument-free, disposable molecular diagnostic tests
• Company 1329 - 1-Bone cement to replace PMMA-based materials, 2-A liquid hydrogel wound dressing able to cure rapidly and in situ
• Company 1330 - Monitoring system to replace the manual assessment of labor progress with real-time/continuous information
• Company 1331 - Delivery of proteins and peptide drugs without burst, with near-zero order release, and with high bioavailability
• Company 1332 - Contrast agents/molecular imaging for detection using a modified porous Silicon (mpSi™) platform
• Company 1333 - Aerolase cosmetic lasers have user-validated superiority on key attributes: efficacy and safety, particularly on hard to treat darker complexions; unique multi-purpose function and portability; yet industry-low cost
• Company 1334 - SutureCross™: Knotless Anatomic Fixation System for double row arthroscopic rotator cuff repair
• Company 1335 - Biodegradable surgical adhesive for seroma reduction in plastic surgery
• Company 1336 - Miniature blood pump, designed to be placed superficially like a pacemaker, for the long-term treatment of chronic heart failure (CHF)
• Company 1337 - Devices that use bio-electric stimulation therapy (bio-current) to treat hard-to-heal wounds
• Company 1338 - Minimally invasive catheter-based ablation technologies to treat atrial fibrillation and other cardiac arrhythmias
• Company 1339 - Transvaginal, ultrasound image-guided HIFU device, capable of real-time guidance and monitoring of therapy
• Company 1340 - A portable breath collection apparatus (BCA) which can collect breath samples virtually anywhere, for highly sensitive laboratory analysis
• Company 1341 - Automatic tools to support image visualization, lesion detection and quantification, temporal evolution assessment, and automatic reporting in chest and abdominal CT scans
• Company 1342 - RNA-based therapeutics
• Company 1343 - Wireless seizure alarm systems for people with epilepsy
• Company 1344 - Arm training device to restore arm movement in stroke patients who have experienced arm paralysis
• Company 1345 - Ophthalmic formulation of mitomycin-C in a single-use kit, for use in the surgical treatment of glaucoma
• Company 1346 - Products to diagnose the risk for heart attacks by means of assessing endothelial function
• Company 1347 - Minimally invasive medical devices for patients who are at risk for or have suffered a stroke
• Company 1348 - AOKit™-bio: an adaptive optics kit for biologists which enhances microscopic imaging
• Company 1349 - Neowater®, a water-based nanotechnology which has physical properties that mimic intracellular water
• Company 1350 - Metabolomic profiling of biomarkers for the diagnosis of early forms of dementia and neurodegenerative diseases
• Company 1351 - A portable oxygen delivery and ventilation system
• Company 1352 - Interventional bronchoscopy devices for lung diseases
• Company 1353 - Advanced endotracheal tube for intubation, fitted with advanced fiberoptic visualization technology
• Company 1354 - Modular hip stem technology and total knee replacement systems
• Company 1355 - First viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF)
• Company 1356 - Fusion and non-fusion spinal implants
• Company 1357 - A device that seals blood vessels after hemodialysis as an alternative to central venous catheters for kidney-dialysis patients
• Company 1358 - Non-invasive ultrasound body contouring
• Company 1359 - Non-invasive, painless, Navigated Brain Stimulation (NBS) for brain diagnostics and therapy
• Company 1360 - Noninvasive breast cancer risk assessment device
• Company 1361 - Low cost, easy-to-use, credit-card-sized devices which will allow on-the-spot quantitative diagnosis
• Company 1362 - Telemedicine paired with state-of-the-art ophthalmologic imaging
• Company 1363 - Devices for treating cardiovascular disease
• Company 1364 - Precision surgical systems for computer-assisted 3D planning, surgical navigation, and surgeon-controlled robotic surgery
• Company 1365 - Female sterilization technology
• Company 1366 - Electromedical/electrotherapeutic equipment
• Company 1367 - Products for the minimally invasive repair of long bone fractures
• Company 1368 - Molecular diagnostic products for laboratories that are intended to enhance medical care by providing early diagnostic information rapidly
• Company 1369 - New pulmonary drug delivery system
• Company 1370 - Next-generation laser therapy
• Company 1371 - Devices for the in-office polypectomy/myomectomy market
• Company 1372 - Low-cost, fast, and accurate molecular diagnostic products
• Company 1373 - EXPANSE Vertebral Body Replacement Device for use in the thoracolumbar spine
• Company 1374 - An oncology visualization system that integrates advanced graphics processing capabilities with proprietary software algorithms to register multiple CT image sets in real-time
• Company 1375 - Minimally invasive, single-use, disposable devices that enable incisionless, transoral procedures for the treatment of a number of upper gastrointestinal problems, including gastrointestinal reflux disease (GERD) and failed bariatric surgery
• Company 1376 - Mobile phone-based data collection for chronic disease management
• Company 1377 - Advanced gene expression and DNA quantification products and services
• Company 1378 - Optical backscatter technology to improve the way cancer is detected and diagnosed
• Company 1379 - Laser, light-based, and radiofrequency devices for aesthetic and medical applications
• Company 1380 - Diagnostic methods using microarray gene expression profiling to determine specific properties of tumors
• Company 1381 - Catheter-based devices which rapidly provide quantitative data to the physician about vessel and stent size, suitable for peripheral and cardiac applications
• Company 1382 - Advanced wheelchair technologies
• Company 1383 - Human bionic devices that can instantaneously interact with the human body to replace or restore biomechanical or physiological functions
• Company 1384 - Cell-based epicardial patch designed to promote blood vessel growth in ischemic cardiac tissue
• Company 1385 - Methods for treating human tissue based on volumetric bipolar radio frequency ablation (RFA), and surface ablation of tissue
• Company 1386 - Infusing normothermic fluids from 10mL/hour-1200mL/minute with 30-second setup through a disposable cassette
• Company 1387 - Technology using opto-acoustics for functional imaging/cancer diagnosis
• Company 1388 - High-intensity focused ultrasound in a catheter to treat atrial fibrillation
• Company 1389 - 1-Alternative to instrument-based viscosity testing; 2-A disposable blood to plasma device for use in micro-fluidic assays; 3-A home-use test for clotting time
• Company 1390 - Portable, easy-to-use consumer device that allows for easy, safe and green disposal of used insulin syringes, lancets and pen needles by vaporizing the sharp
• Company 1391 - Site-specific catheter-guided system to deliver drugs and biologics directly to the adventitia
• Company 1392 - Device based therapy targeting ischemic brain stroke and chronic heart failure
• Company 1393 - Integrated wireless monitoring
• Company 1394 - Non-invasive robotic radiosurgery system for cardiac ablation
• Company 1395 - Ceramic components for spine, orthopaedic, and other implant needs
• Company 1396 - Target-specific recombinant human protein focused on spinal fusion surgery
• Company 1397 - Patient controlled analgesia device for pain management
• Company 1398 - Less invasive orthopaedic implant solutions employing advanced pliable structured materials and innovative designs
• Company 1399 - Dual function, automatic, handheld sinus irrigator and aspirator for OTC consumer use
• Company 1400 - Computer-integrated robotic instrumentation/navigation tools for orthopedic surgery
• Company 1401 - Next-generation disposable colonoscope incorporating diagnostic/therapeutic capabilities allowing for a potentially sedation-less treatment
• Company 1402 - Total hip replacement system that addresses resistance to wear and resistance to dislocation with ceramic and double mobility
• Company 1403 - Percutaneous mitral valve replacement system for treatment of mitral regurgitation
• Company 1404 - Non-invasive continuous glucose monitoring device, for patients with diabetes, based on a multi-sensor platform
• Company 1405 - Growth factor and biomaterial addressing the needs of spinal fusion, osteochondral defects, osteoarthritis, dental medicine, and other indications
• Company 1406 - Open-sky, cryogen-free, superconductive MRI scanner that uses a U-shaped magnet with no barriers in between the patient and the environment for orthopaedic, general purpose, and interventional applications
• Company 1407 - Minimally invasive retractors for pelvic surgery to optimize pneumoperitoneum pressure and patient position (OP5)
• Company 1408 - Handheld device which measures the amount of calories a person requires to maintain body weight
• Company 1409 - Intelligent nasal drug delivery devices for topical, systemic and nose-to-brain applications
• Company 1410 - Developing a fully implantable extra-aortic counterpulsation device designed to provide long-term, cost-effective treatment and significantly improve quality of life for heart failure patients
• Company 1411 - An absolutely non-invasive, radiation- and side-effect free electro physiological high speed cardiac diagnostic system to identify upcoming heart attacks and sudden cardiac deaths
• Company 1412 - DART is utilizing an interstitial radiation source that by nuclear decay recoil mechanism emits high-energy alpha particles widely dispersed by diffusion and by convection in the tumor mass
• Company 1413 - Producer of surgical devices including a self-attaching hernia patch, anti-clog surgical drain, and cavity implosion device
• Company 1414 - Non-surgical serum based cure, proven effective for PAD, Diabetic and Cardiovascular disorders
• Company 1415 - Portable and networked medical devices such as handheld ultrasounds
• Company 1416 - Single-use rigid endoscopes, with superior image quality, at a reduced per-use cost
• Company 1417 - Providing private and hospital-based OB/GYNs, Perinatologists, and Radiologists with integrated reporting and image management systems
• Company 1418 - Minimally invasive ophthalmic device therapy for Dry Macular Degeneration and other blindness causing diseases
• Company 1419 - Minimally invasive surgical technology that uses ionizing radiation to treat wet age-related macular degeneration (AMD)
• Company 1420 - An automated blood glucose monitor for the intensive care unit using near infra-red spectroscopy
• Company 1421 - Human Globin, a biopolymer to replace animal collagens in dermal fillers and create biomaterials for tissue repair
• Company 1422 - Indigo Orb, Inc is a technology leader in "Automatic Detection of Epidural Cavity"
• Company 1423 - Developing and marketing EEG systems, tools and services for Neurologists, Neurosurgeons, and Neuroscience Researchers
• Company 1424 - Orthopedic products, specifically for upper and lower extremity small bone applications
• Company 1425 - Lumbar system for dynamic stabilization without fusion, artificial discs, and minimally invasive surgery systems
• Company 1426 - Reintroducing CHYMOPAPAIN, the only proven minimally-invasive therapy for herniated discs; it allows nuclear regeneration.
• Company 1427 - 1-Lumbar cage with integrated fixation screws, 2-Pedicle screw product line, 3-Access systems and implants for use in minimally invasive surgery (MIS)
• Company 1428 - Surgical adhesives that serve to augment or replace sutures and staples/tacks
• Company 1429 - Revisable cervical and lumbar total disc replacement that can be converted to fusion
• Company 1430 - Proprietary, non-fusion spinal motion preservative total disc replacement technology (ErgoFlex) that provides permanent solutions for lower back (lumbar) area disc problems. The technology is easily adaptable to the entire spine and the company's next target area is the neck (cervical).
• Company 1431 - Two clinically proven lumbar, motion-preservation spinal implants that offer surgeons: 1-a lumbar joint replacement that has provided superior treatment over fusion and disc replacement, for patients with degenerative lumbar joint disease and 2-a posterior dynamic stabilization system used to restabilize the spine after surgery for spinal stenosis, as an alternative to lumbar fusion
• Company 1432 - Building on an exclusive intellectual property platform for both fusion and non-fusion products
• Company 1433 - Tumor necrosis factor alpha (TNF-a) inhibitor therapy for treatment of chronic persistent radiculopathy (including sciatica) related to disc herniation.
• Company 1434 - Spinal implants, cervical, thoracolumbar, interbody, bone substitutes, motion preservation
• Company 1435 - Biocellulose technology that eliminates the risks/complications/limitations inherent in animal, human, and synthetic biomaterials
• Company 1436 - Wireless patient vital signs monitoring
• Company 1437 - Disease management system for early detection of heart failure using a noninvasive cardiovascular-sleep prognostic marker
• Company 1438 - 1-Soft tissue attachment nanotechnology, 2-Bioactive/biocompatible/osteoconductive synthetic bone filler, 3-Biodegradable fiberglass fiber & composites
• Company 1439 - Noninvasive blood glucose monitor that will measure glucose in sweat in a disposable dermal patch
• Company 1440 - Affordable thermal systems that are portable, easy-to-use, and comfortable to wear
• Company 1441 - High Intensity Focused Ultrasound for incisionless male surgical sterilization
• Company 1442 - Ambulatory infusion pumps and disposables that require no programming and use pre-filled solution containers
• Company 1443 - ViaDerm - home use transdermal drug delivery system creating microscopic passageways in the top skin layer
• Company 1444 - Tools for enabling adult stem cell based regenerative medicine
• Company 1445 - Lectin-based cell adhesion technology which enables stents that traffic cells in the bloodstream
• Company 1446 - Programmable lab-on-a-chip platform for applications ranging from drug discovery to consumer diagnostics
• Company 1447 - Technology that enables real-time tracking of the position and orientation of any interventional tool - biopsy device, catheter, endoscope, ablation probe, marker dispenser, etc.
• Company 1448 - Blood tests for the early detection of breast cancer, ovarian cancer, lung cancer, Alzheimer's, and other serious diseases where significant unmet clinical needs exist
• Company 1449 - Spinal implants utilizing elastomeric polymers for non-fusion treatment of disc degeneration
• Company 1450 - ECG software for assessing acute ischemia and cardiac safety surrogates in clinical trials
• Company 1451 - Resorbable pegylated hydrogel for surgical wound sealing/adhesion prevention/sustained and targeted drug delivery
• Company 1452 - The Sensation
• Company 1453 - Robot-assisted stroke therapy devices
• Company 1454 - Endothelial management - less trauma combined with new agents for improved healing in vascular interventions
• Company 1455 - Digital Pulse Analyzer - provides early detection of arterial wall stiffness and biological age of arteries
• Company 1456 - Diagnostic platform with a test for measuring unbound Bilirubin for the management of newborn jaundice
• Company 1457 - Percutaneous light activation reduces intra-abdominal fat, returning Type 2 diabetic patients towards normoglycemia
• Company 1458 - 1-Cartilage implant for the knee, 2-Injectable cell therapy for the spinal disc/nucleus, 3-Bone graft extender to treat spinal deformities
• Company 1459 - Protein free induction of endochondral ossification, no human origin, not contagious, no soft tissue ossification
• Company 1460 - 1-Instant-on/instant-off proximal occlusion funnel catheter, 2-Scoring balloon with drug delivery capability
• Company 1461 - An internal adhesive biotechnology designed for strength, biocompatibility, and ease-of-use with applications in cardiovascular surgery
• Company 1462 - Technology that prepares the spinal disc for a nucleus replacement/minimally invasive fusion device
• Company 1463 - Tissue repair devices exploiting shear force transfer and large-interface substrates for adherent new tissue formation
• Company 1464 - Advanced skin biopsy and wound healing solutions to dermatology, cosmetic, primary care, and oncology clinicians
• Company 1465 - Advanced optical systems/services that are changing the way doctors evaluate and treat the eye
• Company 1466 - Non-invasive cardiac output monitoring to assess stroke volume, contractility, cardiac output, cardiac index, and thoracic fluid content
• Company 1467 - 1-Cardiovascular-directed growth factor therapeutics; 2-Endovascular catheter-based system to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events
• Company 1468 - A drug delivery platform that approaches the endovascular bifurcation challenge from a completely different angle
• Company 1469 - A bioactive ceramic that delivers better/faster spine fusion and bone repair
• Company 1470 - Percutaneously delivered implantable system to treat mitral valve regurgitation and improve congestive heart failure
• Company 1471 - Electro-grafting coating technology for implantable biomedical applications; used for the fast healing post drug-eluting-stent (DES) implantation (avoiding late stage thrombosis)
• Company 1472 - Noninvasive medical device for the treatment and prevention of obesity using controlled hypoxia
• Company 1473 - An implantable ophthalmic device to treat vision correction associated with Age-Related Macular Degeneration (AMD)
• Company 1474 - Accommodating and multifocal phakic IOLs, CE-approved for $ billion refractive IOL market
• Company 1475 - Biocompatible polymer implant to prevent or reverse the progression of chronic heart failure and mitral valve regurgitation
• Company 1476 - Noninvasive device used in the differential diagnosis of disc or facet mediated low back pain
• Company 1477 - Surgical stapling devices for open and laparoscopic procedures developed for the growing China market
• Company 1478 - The first-and-only, fully self-contained, low-cost, and market-proven disposable iontophoretic patch - topical drug delivery platform for enhanced penetration and efficacy
• Company 1479 - IBraces - 100% customized, invisible orthodontic braces designed for efficient, effective treatment of teens and adults
• Company 1480 - Flash Ultrasound
• Company 1481 - Free-floating optical probe with multiple LD scanning and magnetic stabilization for noninvasive blood glucose monitoring
• Company 1482 - Repositionable/removable percutaneous heart valve, precision controlled delivery device, and calcified valve encapsulation system
• Company 1483 - Next-generation estrogen-based drug-eluting coronary stent and an orthopedics/sports injury pain management device
• Company 1484 - Heart pump that achieves superior flow and pressure performance, mimicking the physiological performance of the human heart, and reducing post-surgery kidney failure, mortality, and complications cost by 50%
• Company 1485 - Porcine-derived tissue devices for ligament, cartilage, bone, and soft tissue replacement and augmentation
• Company 1486 - MIS platform technologies for creating cavities in tissue and partially molding an orthopedic implant in situ
• Company 1487 - Orbital atherectomy for the treatment of peripheral vascular disease
• Company 1488 - Functional brain imaging centers that identify Alzheimer's, brain injury, stroke, ADHD, bipolar, depression, anxiety, OCD
• Company 1489 - A protein therapeutic biotreatment that regresses solid tumors and protects against relapses
• Company 1490 - Analyze, search, store, mine, share and unlock the power of digital tissue images
• Company 1491 - Smart devices to harness human physiology for health care, industrial safety, and law enforcement applications
• Company 1492 - Naturally-derived/non-crosslinked/collagen-based extracellular matrix to repair/remodel damaged tissues
• Company 1493 - Facet fixation system that is a less-invasive/faster alternative to pedicle screw fixation
• Company 1494 - The Extremity Compartment Syndrome (ECS) System is being launched as the only FDA-cleared continuous monitoring device that assists physicians with diagnosing a limb-threatening complication
• Company 1495 - Shielded reciprocating tissue sculpturing instrument, able to navigate into neural foramen to relieve nerve compression
• Company 1496 - 1-LIFEBACK® Spine Programs for non-operative and post-operative spine patients and 2-the LTX 3000® Rehabilitation System
• Company 1497 - Stable and extractable self locking intramedullary nails and proximal femoral fixation
• Company 1498 - Emperor Mobile Spinal Disc, P.E.E.K Cages, Pedicle Screw System, and Saturn Hip Resurfacing
• Company 1499 - Rapid table-mounted retraction/surgical site access for MIS placement of hip/knee/shoulder/spine implants
• Company 1500 - Lumbar dynamic stabilization with MIS compatibility and pedicle screws
• Company 1501 - Real-time image-guidance technology with an FDA-accepted accuracy claim of +/-1mm at 1 meter
• Company 1502 - Noninvasive, ambulatory, portable, 3-D traction technology providing an effective and unique therapy for spinal disorders
• Company 1503 - Fusion technology platforms and second-generation artificial discs for the lumbar and cervical spine
• Company 1504 - A biological and mechanical solution to annular repair and spine fusion
• Company 1505 - Low-profile implants/less invasive surgical instruments to treat spinal disorders utilizing fusion and non-fusion technologies
• Company 1506 - A CE-marked resorbable plating system for cervical fusions allowing for load sharing
• Company 1507 - Biomaterials-based product that augments or replaces the diseased nucleus pulposus of the spinal disc
• Company 1508 - Nitric oxide-based therapies to accelerate healing of tendon, bone, and other musculoskeletal tissue
• Company 1509 - Drug product for the treatment of acute spinal cord injury, cancer, macular degeneration, and glaucoma
• Company 1510 - Synthetic bone that duplicates the microstructure, composition, and performance of human bone
• Company 1511 - Implanted oscillating field stimulation device which regenerates acute and sub-acute damaged spinal cord nerve tissue
• Company 1512 - PuraMatrix injectable synthetic nanofibrous hydrogels for bone, cartilage and soft tissue regeneration, and drug delivery
• Company 1513 - Noninvasive device providing substitute vestibular sensory information through the tongue for treatment of balance disorders
• Company 1514 - Naturally occurring neuropeptide to treat ischemia associated with myocardial infarction, heart failure, and angina
• Company 1515 - Miniature/patient-controllable/valved catheter to improve quality of life/decrease urinary tract infections in patients suffering urinary retention
• Company 1516 - Phase-shifting technology for Contrast Ultrasound imaging
• Company 1517 - Innovative, implantable, combination drug+device products that utilize novel biomaterials. TYRX's first commercially available products include the AIGISRx(R) Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs).
• Company 1518 - Laparoscopic surgical access technology based on a No-Seal platform
• Company 1519 - Theramers
• Company 1520 - Respiratory diagnostics for noninvasive assessment of airway acidification in Asthma, COPD, and GERD
• Company 1521 - A "preventative" vaccine for HIV-AIDs
• Company 1522 - Post-proteomics multiplexed MS-based diagnostics/theranostics linked to drug development and personalized medicine
• Company 1523 - Image-guided therapy for metastatic liver disease
• Company 1524 - Biomaterial that regulates resorbability and enhances bone regeneration
• Company 1525 - Drug/device products for post-operative pain and orthopedic drug delivery indications using syntinate synthetic absorbables
• Company 1526 - Ultrasonic medical devices for minimally invasive therapeutic procedures for treatment of cancer/other healthcare purposes
• Company 1527 - Multi-channel implantable microelectrodes for deep brain stimulation and recording, enabling enhanced neuromodulation therapies
• Company 1528 - Aesthetic treatment device using collimated high-energy light and laser, delivered simultaneously by fiber delivery system
• Company 1529 - A remotely controlled, wireless-powered implantable 230-channel nerve stimulator built on a 15
• Company 1530 - Real-time, noninvasive monitoring of blood loss, anemia, and other vital blood measurements
• Company 1531 - Small/portable/handheld device for diagnosing brain hematomas
• Company 1532 - Fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify lipid rich plaques in the coronary arteries
• Company 1533 - Laparoscopic surgeons maintain direct control of the laparoscope movement/placement with GMP's Laparocision
• Company 1534 - Rapid testing systems led by the Growth Direct
• Company 1535 - World's smallest leg compression device for the prevention of deep vein thrombosis (DVT) in surgical patients, as a safe and effective alternative to Lovenox, for a significantly reduced price
• Company 1536 - Ultraviolet light technologies for the inactivation of RNA viruses in/out of the body
• Company 1537 - Minimally invasive percutaneous neuromodulation pain therapy
• Company 1538 - The Axya Shoulder Fixation System generates ultrasonic energy for knotless suture welding in shoulder surgery
• Company 1539 - Gene-based products for the diagnosis and treatment of spinal disorders
• Company 1540 - A platform aerosol drug delivery nebulizer device for multiple- and single-use applications with disposables
• Company 1541 - Non-invasive continuous measurement of tissue oxygenation for various intraoperative and post-operative applications
• Company 1542 - Vascular stents and grafts with increased patency by improved flow dynamics, reducing stenosis and restenosis
• Company 1543 - 1-Next-generation liquid embolic for treating cerebral aneurysms and arteriovenous malformations (AVMs); 2-Two wound management products that will be out-licensed
• Company 1544 - SurfLink
• Company 1545 - Bifurcated coronary stent
• Company 1546 - Monitoring products based on microsensor technology allowing minimally invasive, real-time measurement of clinical chemistry parameters and therapeutic drug concentrations
• Company 1547 - Noninvasive, outpatient bariatric device for overweight/obesity
• Company 1548 - A suite of tools for automated CT Angiography (CTA) diagnostics for Coronary Artery Disease
• Company 1549 - Magnetically actuated telescopic intramedullary (IM) nail activated by an induced low power directional magnetic field
• Company 1550 - Transdermal delivery system of levodopa (L-DOPA) for the treatment of Parkinson's Disease
• Company 1551 - Immediate, active, device-less, and painless topical drug delivery, of small/macromolecules, for local/systemic indications
• Company 1552 - Endotracheal tube with video, self-locking orthopedic implants, structured TPN lipids, cell therapy for cancer, etc.
• Company 1553 - Products that digitize manual breast examination tissue elastic properties into objective computerized visual maps/reports
• Company 1554 - Technology for the manipulation of adult stem cells to repopulate chronically diseased liver tissue
• Company 1555 - Non-invasive airway clearance in ICU patients to prevent ventilator associated pneumonia
• Company 1556 - Unique add on and removable needle safety product that fits to standard glass/plastic syringes
• Company 1557 - Medical devices utilizing radiofrequency and microwave energy which are cost-effective and clinically relevant
• Company 1558 - Non-invasive screening of Peripheral Arterial Disease (PAD), combining postural/infrared blood volume testing
• Company 1559 - Tissue fixation implants, injectable bone grafting biomaterials, and tissue scaffolds with drug releasing properties
• Company 1560 - Miniature implantable, continuous blood glucose sensor for diabetics, incorporating noninvasive wireless monitoring
• Company 1561 - Coronary guidewire, to provide real-time ultrasonic measurement of coronary arteries to determine stent size and apposition without exchange of catheters
• Company 1562 - Bioabsorbable, bioactive, and drug-releasing medical device products for various fields of surgery
• Company 1563 - 1- Interventional single-use cardiac support device and drug delivery platform, 2- Implants for use in/with magnetic resonance imaging (MRI) systems
• Company 1564 - Endoscopically-placed devices to prevent GERD, obesity, and irritable bowel syndrome (IBS)
• Company 1565 - Cellular implants for orthopedic, trauma, and spinal applications based on a biological form stable matrix
• Company 1566 - SmartStep
• Company 1567 - Dynamic optimization of pacing intervals according to hemodynamic sensors for CRT devices
• Company 1568 - Neuro-monitoring systems for brain protection and stroke acute care in stroke units, cardiovascular ORs, during stenting, and in the ICU
• Company 1569 - Medical devices that enable diabetes disease management and the prevention of lower extremity amputations
• Company 1570 - Customized miniature disposable stereoscopic cameras that provide 3D vision, measurements, and image fusion in real-time
• Company 1571 - Infusion catheter for treatment of tumors which are unresponsive to systemic chemotherapy by the local delivery of drugs and other agents
• Company 1572 - Non-invasive imaging tool designed to provide automated, 3-D ultrasound images of the breast
• Company 1573 - RFID hardware and software platform for test tubes/ apheresis device for blood component separation
• Company 1574 - Saliva-based consumer diagnostic systems, which enable the development of personalized therapeutics
• Company 1575 - Disposable, noninvasive, pump-less, and valve-less automatic blood pressure monitor "on-a-chip"
• Company 1576 - Noninvasive neural vision enhancement
• Company 1577 - Nanotechnologies for use in orthopedic implants, dental implants, and stents
• Company 1578 - Specialty and standard electrophysiology catheters that have superior performance, advantageous features, and are affordable
• Company 1579 - Dedicated angioplasty and stent systems for the treatment of arterial bifurcations
• Company 1580 - System to ablate cardiac tissue as a means to potentially treat atrial fibrillation
• Company 1581 - Point-of-care IVD platform that provides rapid, accurate, automated laboratory testing using low cost, disposable biochips
• Company 1582 - Interventional MRI technology for cardiovascular imaging including detection/treatment of vulnerable plaque
• Company 1583 - System analyzes a patient's susceptibility to cardiac arrest and consequent need for implantable defibrillator
• Company 1584 - Patient recovery system for cosmetic and reconstructive surgery
• Company 1585 - Microscope slide scanners and information management software that enable the digitization of pathology
• Company 1586 - SutureLock - a versatile suture-securing knot-replacement device for endoscopic wound approximation
• Company 1587 - Multi-Sensing Wireless Catheter platform attached along the GI-Uro tract detecting GERD, incontinence, and other abnormalities
• Company 1588 - Noninvasive medical device providing low-risk hypoxic treatment that induces appetite suppression and weight loss
• Company 1589 - Minimally invasive telemetric and continuous measurement of left atrial blood pressure at heart failure
• Company 1590 - Catheter-based photoreactive treatment system for endovascular intervention in coronary and peripheral atherosclerotic disease
• Company 1591 - Transcatheter mitral valve repair technology offering minimally invasive treatment option for mitral regurgitation/congestive heart failure
• Company 1592 - A platelet reactivity test to measure the effect of anti-platelet drugs, particularly aspirin and Plavix
• Company 1593 - OmniWave(R) catheter-based technology that delivers transverse ultrasonic energy to targeted thrombus in a diseased blood vessel, without damaging the surrounding vessel walls
• Company 1594 - A portable laseroptical system for noninvasive differentiation between ischemic stroke and spontaneous intracerebral hemorrhages
• Company 1595 - Alginate-based embolic material designed to fill blood vessel defects thereby displacing blood pressure effects and preventing vessel rupture
• Company 1596 - A wearable continuous ultrafiltration device that removes fluid overload in patients with Congestive Heart Failure
• Company 1597 - Minimally-invasive cardiac implantable devices for treating mitral valve regurgitation without atriotomy or cardiopulmonary bypass
• Company 1598 - Surgical and percutaneous cardiac valve repair
• Company 1599 - Percutaneous mitral valve repair simulating precision of surgical annuloplasty
• Company 1600 - Pressure and flow sensing systems for vascular and other applications
• Company 1601 - Advanced ECG-heart sound analysis to enable superior diagnosis/monitoring of CHF/ACS patients
• Company 1602 - Minimally invasive interventional radiology/vascular surgery devices
• Company 1603 - PeriVasc
• Company 1604 - Perfusion monitoring for preventing septic shock, the greatest hospital mortality
• Company 1605 - A noninvasive test for endothelial dysfunction using digital (fingertip) thermal monitoring
• Company 1606 - Stentless aortic valve prosthesis to be delivered via catheter
• Company 1607 - Catheter-based therapy which increases cerebral perfusion for the treatment of ischemic stroke and vasospasm
• Company 1608 - Catheter-based devices to reconstruct the ventricle and downsize the heart volume
• Company 1609 - Non-invasive device using muscular counter pulsation (MCP) technology for the treatment of acute and chronic heart failure (CHF) in a clinical, ambulatory, or at-home setting
• Company 1610 - 1-Bio-therapeutic designed from autologous stem cells and committed to a cardiac lineage before implantation, 2-Corresponding catheter for accurate transmyocardial injection
• Company 1611 - Minimally invasive device-based technologies targeting the treatment of hemodynamic instability and perfusion
• Company 1612 - Peptide-based therapeutic to enhance stent/graft patency
• Company 1613 - Biomimetic coronary stent coating that prevents restenosis/reduces the need for extended courses of dual antiplatelet therapy
• Company 1614 - Disposables for drawing blood -- percutaneous or from a catheter -- neonates to geriatrics
• Company 1615 - Electrode sensor array, with integrated lead wires, simple, accurate and repeatable ECGs
• Company 1616 - In vivo plasmapheresis and ultrafiltration to remove excess fluid from CHF patients in clinical trials
• Company 1617 - Noninvasive therapeutic ultrasound to enhance perfusion for treatment of acute myocardial infarction
• Company 1618 - Affordable handheld metabolic monitor (indirect calorimeter) with both medical and consumer weight management applications
• Company 1619 - Unique microsphere-based technology for chronic/acute wounds
• Company 1620 - Technologies that utilize flexible cross linking and sterilization processes which stabilize and sterilize biological tissue for use in orthopedic, wound, oral/dental, spine and neurological, breast, abdominal and thoracic applications
• Company 1621 - Devices for mechanically induced bone growth, together with a "smart device" system for risk management
• Company 1622 - Nitric oxide releasing surface treatments for enhanced biocompatibility in medical devices
• Company 1623 - Automated implantable pump systems for moving fluids around inside the body
• Company 1624 - Minimally invasive surgical access system used in laparoscopic surgery
• Company 1625 - Long-term, miniature drug delivery implant with physician- controllable, zero-order release characteristics
• Company 1626 - 1-Single-use, patented, disposable, hemorrhoid banding system; 2-Two-tier colon cancer diagnostic screen, Fecal Occult Blood Testing (FOBT)
• Company 1627 - Interventional catheter-based system precisely measures stent and arterial size and cardiovascular repair tissue patch products
• Company 1628 - Device for the treatment of mitral regurgitation and heart failure without requiring open heart surgery
• Company 1629 - Light-based therapy for eradication of ulcer-causing Helicobacter pylori
• Company 1630 - Non-invasive medical radar imaging for cardiopulmonary ambulatory monitoring and diagnosis
• Company 1631 - Enteric Dialysis with Kibow Biotics - a food-grade microbial Gel cap formulation towards kidney failure applications
• Company 1632 - IYIA has developed a proprietary, clinically effective device, O2Misly, for treating slow healing foot wounds, primarily diabetic foot ulcers
• Company 1633 - Genetic and personal history based testing to predict age-specific risk of breast cancer diagnosis
• Company 1634 - Controlled fluid delivery system for every medical application without batteries or power cords
• Company 1635 - Non-contact intelligent medical vigilance for the hospital
• Company 1636 - Capture and analysis of heart sounds leading to rapid and accurate diagnosis of cardiac pathologies
• Company 1637 - Blood test that screens/diagnoses cervical cancer without need of a cervical exam/pap smear
• Company 1638 - Implantable Left Ventricular Assist Device (LVAD) for heart failure
• Company 1639 - Bioabsorbable drug eluting stents and stent coatings for treatment of vulnerable plaque and coronary stenosis
• Company 1640 - Electronic pill for oral delivery of low bioavailability drugs
• Company 1641 - Microsyringe delivery of cells, genes, and drugs to the vasculature/deep tissues of the body
• Company 1642 - Percutaneous noninvasive heart valve replacement
• Company 1643 - Molecular FingerPrinting process for early-stage diagnosis of cancer, enabling point-of-care therapeutics based on gene regulation
• Company 1644 - Percutaneous access management system to provide early ambulation/eliminate major complications, leaving nothing behind in patient
• Company 1645 - Totally implantable LVAD that does not interface with circulating blood
• Company 1646 - Blood test for breast cancer measuring 5 protein biomarkers using super-sensitive ELISA with 95% accuracy
• Company 1647 - Ablation technology that delivers radiofrequency energy endoscopically, to eliminate Barrett's esophagus and prevent esophageal cancer
• Company 1648 - A device for the left atrial appendage for stroke prevention in patients with atrial fibrillation
• Company 1649 - Noninvasive monitor to measure exhaled nitric oxide for the management of asthma
• Company 1650 - Microplate-based electronic biosensor system for label-free, real-time cell based assays
• Company 1651 - Interactive intraoperative CT scanning technology for image-guided interventions
• Company 1652 - High Intensity Focused Ultrasound for minimally invasive thermal treatment of disc herniation without disc penetration
• Company 1653 - Percutaneous systems to treat lower back pain
• Company 1654 - Least invasive approach for the delivery of lumbar fusion and motion preservation therapies
• Company 1655 - Telemeterized natural motion elastomer disc
• Company 1656 - Interspinous process implant to treat Lumbar Spinal Stenosis (LSS)
• Company 1657 - Clinical expertise, facility development, new technology, and business services including marketing and contracting
• Company 1658 - Advance and commercialize less invasive spinal deformity surgical treatment without fusion
• Company 1659 - Lumbar, thoracic, and cervical fusion devices including less invasive instrumentation; lumbar and cervical artificial discs
• Company 1660 - Lumbar spine motion preservation via dynamic stabilization utilizing a semi-rigid rod and screw system
• Company 1661 - 1-Stand-alone anterior lumbar IBF device and 2-Stand-alone cervical IBF device
• Company 1662 - Compliant artificial lumbar disc with graduated modulus for restoration of normal spine biomechanics/enhanced durability
• Company 1663 - 1-Synthetic alternatives to autograft/cadaver-based bone material, 2-Surgical hemostat as an adherent matrix/impermeable barrier to blood flow, 3-Bone augmentation material for injections in osteoporotic spines to treat vertebral compression fractures
• Company 1664 - Orthopeutics, LP introduces Intrabrace a new non-surgical, injectable treatment for resisting spinal curvature in scoliosis.
• Company 1665 - Bioactive synthetic bone graft substitute that is osteostimulative, osteoconductive, antimicrobial, and hemostatic
• Company 1666 - Next-generation fusion, motion sparing, and minimally invasive spinal implant products
• Company 1667 - Minimally invasive fusion system
• Company 1668 - Fluidjet devices for open and MIS fusion, discectomy, artificial nucleus, and artificial disc procedures
• Company 1669 - Osteogenica - bone marrow concentration system
• Company 1670 - Dascor Arthroplasty System, spinal implants technology
• Company 1671 - BioDisc, a nucleus replacement product based on an injectable, flexible, and durable protein hydrogel technology
• Company 1672 - Second-generation, viscoelastic artificial disc restoring native function to the spine
• Company 1673 - Three-dimensional surgical visualization technologies and expanding portfolio for digital surgical environment and digital healthcare network
• Company 1674 - Real-time disposable stereotactic navigation devices for biopsy/targeted therapy compatible with CT, fluoroscopy, and MRI
• Company 1675 - Minimally invasive cancer therapy using Magnetically Energized (ME) Thermotherapy
• Company 1676 - Magneto-Optical Enantiomeric Detection (MOPED) for real-time, non-contact analysis of chiral pharmaceuticals
• Company 1677 - First noninvasive, transcutaneous sensor array that continuously monitors peripheral circulation and/or core body temperature
• Company 1678 - Disposable balloon cervical dilator for improved uterine access that decreases pain, avoids tearing and perforations
• Company 1679 - Biological therapeutics for the treatment of neurological disorders including: Alzheimer's disease, epilepsy, Huntington's disease, Parkinson's disease, and neuropathic pain
• Company 1680 - Complete pre-configured system for implementing minimized cardiopulmonary bypass
• Company 1681 - Catheter-based sealing of heart defects associated with stroke, migraine headaches, and other brain attacks
• Company 1682 - Technology for imaging peripheral nerves in regional anesthesiology, pain management, and other markets
• Company 1683 - Nanomagnetic particles enabling controlled drug delivery and elution for drug targeting and medical device applications
• Company 1684 - MRI-compatible, precision- guided laser therapy for the treatment of brain tumors
• Company 1685 - Implantable blood pump with magnetic levitation technology for patients suffering from heart failure
• Company 1686 - Virtual Bone Biopsy MRI scanner add-on, allowing noninvasive imaging of bone microstructure for osteoporosis monitoring
• Company 1687 - The Renaissance(TM) Surgical Guidance System is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art operations that raise the standard of care with better clinical outcomes
• Company 1688 - Nanotechnology-based cancer therapy with contactless activation of tumor-specific nano-particles, adaptable to all solid tumors
• Company 1689 - Point-of-care platform technology for assessing risk of cardiovascular disease and renal dysfunction
• Company 1690 - Continuous blood gas monitoring and cardiac output measurement for the intensive care unit
• Company 1691 - Non-blood contacting, active implantable direct cardiac compression device for the treatment of CHF
• Company 1692 - Augmented reality simulators that train surgeons in the skills required for minimally invasive surgery
• Company 1693 - Continuous, non-invasive glucose monitor for tight glycemic control at the hospital and at home
• Company 1694 - ERBLAN MIS Surgical Devices allow safe entry into virtually any actual or potential anatomical space
• Company 1695 - Technology that non-invasively measures/monitors mechanical heart function and disease utilizing a disposable brachial cuff
• Company 1696 - Endovenous ablation system for varicose veins with 1320 nm CoolTouch laser
• Company 1697 - Micro-porous ceramic wound treatment device that creates optimal conditions for normal wound healing
• Company 1698 - Direct, real-time vision through flowing blood to guide therapy inside the heart and vessels
• Company 1699 - Cath lab solution providing rapid onset of circulatory support in patients with acute heart failure
• Company 1700 - Novel bone void filler made from magnesium which provides a resorbable and biocompatible binding platform for synthetic bone grafting following trauma
• Company 1701 - AepEX auditory evoked potential depth of anesthesia monitor and aepEX-Fusion servo-controlled anesthesia delivery system
• Company 1702 - Posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion
• Company 1703 - Site-specific biological and drug delivery
• Company 1704 - HistoScanning(TM) is an innovative imaging-based modality available in the Tissue Characterization market; the only one offering accurate 3D detection and localization of cancer lesions
• Company 1705 - Non-irritating dry electrodes now enabling long-term cardiac monitoring
• Company 1706 - Non-incisional female sterilization
• Company 1707 - Biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care
• Company 1708 - Portable, compact, easy-to-use automated external defibrillators with full energy delivery and complete resuscitation solutions
• Company 1709 - Rapid, point-of-care in vitro diagnostics
• Company 1710 - Endoscopy systems allowing physicians to see very small, early-stage cancer and subtle pre-cancerous lesions
• Company 1711 - Surgical instruments employing thermal welding technology to seal and cut tissue
• Company 1712 - Minimally invasive disc replacement for chronic back pain
• Company 1713 - A smart, communicating cigarette case, online support, and daily e-mails delivering an effective stop-smoking method
• Company 1714 - A wireless personal emergency alert system that integrates with, and enhances, existing implanted medical devices
• Company 1715 - Artificial total intervertebral disc capable of normal physiological movement and weight loading
• Company 1716 - Catheters designed to diagnose, terminate, and treat cardiac arrhythmia during EP and ablation procedures
• Company 1717 - Conservative Motion Preservation technology including minimally invasive facet joint replacement
• Company 1718 - BioSilicon, nano-structured porous silicon for applications in drug delivery, diagnostics, tissue engineering, and orthopedics
• Company 1719 - System that prevents embolic events by removing plaque and thrombus found in diseased arteries
• Company 1720 - Bioresorbable polymer implants for use in a variety of orthopedics and spine surgical applications
• Company 1721 - Liposomal formulation of recombinant IL-2 for use as chemotherapy or cancer vaccine adjuvant
• Company 1722 - Helical stent providing enhanced abilities and flexibilities in drug delivery, scaffolding, and embolic protection
• Company 1723 - Trabectome, an FDA-cleared, minimally invasive medical device technology for the treatment of open angel glaucoma
• Company 1724 - ClearSolution represents the next wave in integrated, intra and interoperative physiologic monitoring. ClearSolution enables a non-invasive, wireless solution for continuous, multi-modal patient monitoring for image-facilitated minimally invasive surgery, improved CAD detection, and remote patient monitoring.
• Company 1725 - Prevention of scarring caused by disease, medical intervention, or trauma via a beta emitting biopolymer
• Company 1726 - Noninvasive, site-specific drug delivery technology to deliver compounds to the posterior segments of the eye
• Company 1727 - Real-time, CT-guided, robotically controlled needle drivers for minimally invasive cancer therapy
• Company 1728 - Automated, continual blood glucose monitoring for critically ill patients
• Company 1729 - Molecular diagnostics based on patented, standardized, next-generation, multi-gene expression (StaRT-PCR) products and high margin services
• Company 1730 - THERMOCEPS - a handheld, wireless device that stops bleeding during surgical procedures using focused, thermal coagulation
• Company 1731 - Interventional catheter system for the mechanical recanalization of arterial chronic total occlusions quickly and reliably
• Company 1732 - Portable automated critical care neuro instruments using advanced digital signal processing technology
• Company 1733 - Monitor for autonomic nervous system displaying sympathovagal balance in real-time for diabetes/ anesthesia/cardiology applications
• Company 1734 - Branched endografts for aortic disease
• Company 1735 - Next-generation biomaterials using bioactive-ceramics technology platform
• Company 1736 - Immunodiagnostics of placental recombinant markers to screen the risk of preeclampsia, preterm delivery, and IUGR
• Company 1737 - Methods for eyebrow lifting, non-thermal loading of degradable matrices, and degradable implants
• Company 1738 - Non-invasive modality for the treatment of insulin resistance/diabetic neuropathy
• Company 1739 - Minimally invasive needle biosensor for in vivo glucose or lactate monitoring of intensive care patients
• Company 1740 - P-15: a small peptide attachment factor for bone formation in orthopedics
• Company 1741 - MIST Therapy using non-contact ultrasound to stimulate healthy cells allowing chronic wounds to heal
• Company 1742 - Arthroscopic surgical devices
• Company 1743 - Electronic device that closes the gap between drugs and surgery in osteoarthritis of the knee
• Company 1744 - Cell-based therapy products for the treatment of heart failure secondary to myocardial infarction
• Company 1745 - A five-carbon carbohydrate that increases cellular energy, improving cardiovascular health and tissue function
• Company 1746 - The most advanced Infrared Light Therapy technology available that is clinically proven to reduce sports injury healing time by >60%, with additional applications for oral tissue and migraines
• Company 1747 - Next-generation non-vascular interventional pulmonary and gastrointestinal stenting technology
• Company 1748 - A revolutionary device that will facilitate broad implementation of extracorporeal CO2 removal and oxygen supplementation resulting in the avoidance of airway intubation, sedation, and invasive mechanical ventilation
• Company 1749 - Intravascular temperature management systems and catheters for cardiac and neuro intensive care patients
• Company 1750 - Implantable devices for the endovascular treatment of hemorrhagic stroke
• Company 1751 - Ultrasound catheters for targeted thermal ablation of tumors

* Corporate License allows for multi-user and/or enterprise wide access.